var title_f16_14_16608="Contents: Pediatric pulmonology";
var content_f16_14_16608=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?17/55/18302\">",
"       Pediatrics",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Pediatric pulmonology",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Pediatric pulmonology",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Asthma epidemiology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/61/15319\">",
"           Chronic asthma in children younger than 12 years: Definition, epidemiology, and pathophysiology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/29/10713\">",
"           Genetics of asthma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/13/7383\">",
"           Natural history of asthma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/12/20682\">",
"           Risk factors for asthma",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Asthma evaluation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/45/30424\">",
"           Approach to wheezing in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/25/26010\">",
"           Chronic asthma in children younger than 12 years: Evaluation and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/27/29112\">",
"           Overview of pulmonary function testing in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/41/1689\">",
"           Wheezing illnesses other than asthma in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Asthma management",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/1/30746\">",
"           Agents affecting the 5-lipoxygenase pathway in the treatment of asthma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/36/33354\">",
"           Alternative and experimental agents for the treatment of asthma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/37/8794\">",
"           An overview of asthma management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/24/20870\">",
"           Anticholinergic agents in the management of acute exacerbations of asthma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/30/37354\">",
"           Chronic asthma in children younger than 12 years: Controller medications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/25/26010\">",
"           Chronic asthma in children younger than 12 years: Evaluation and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/47/39670\">",
"           Chronic asthma in children younger than 12 years: Quick-relief agents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/18/31014\">",
"           Delivery of inhaled medication in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/60/7114\">",
"           Major side effects of inhaled glucocorticoids",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/47/27386\">",
"           Major side effects of systemic glucocorticoids",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/53/854\">",
"           Peak expiratory flow rate monitoring in asthma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/57/36760\">",
"           The use of inhaler devices in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/57/11161\">",
"           Theophylline use in asthma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/9/44184\">",
"           Trigger control to enhance asthma management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/42/30376\">",
"           Use of medication nebulizers in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/15/31991\">",
"           What do patients need to know about their asthma?",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Asthma triggers",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/0/39944\">",
"           Aspirin exacerbated respiratory disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/30/1513\">",
"           Exercise-induced bronchoconstriction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/42/34472\">",
"           Nocturnal asthma",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Congenital abnormalities",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/29/29144\">",
"           Bronchopulmonary sequestration",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/27/29114\">",
"           Congenital anomalies of the intrathoracic airways and tracheoesophageal fistula",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/11/44214\">",
"           Congenital lobar emphysema",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/50/810\">",
"           Congenital pulmonary airway (cystic adenomatoid) malformation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/39/25207\">",
"           Pectus carinatum",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/41/18071\">",
"           Pectus excavatum: Etiology and evaluation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/12/21704\">",
"           Pectus excavatum: Treatment",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Control of breathing",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/13/43223\">",
"           Management of apnea of prematurity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/4/12360\">",
"           Pathogenesis, clinical presentation, and diagnosis of apnea of prematurity",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cystic fibrosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/22/41322\">",
"           Cystic fibrosis: Antibiotic therapy for lung disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/26/29095\">",
"           Cystic fibrosis: Assessment and management of pancreatic insufficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/49/28442\">",
"           Cystic fibrosis: Clinical manifestations and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/45/27351\">",
"           Cystic fibrosis: Clinical manifestations of pulmonary disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/11/39095\">",
"           Cystic fibrosis: Genetics and pathogenesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/26/32167\">",
"           Cystic fibrosis: Investigational therapies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/24/15754\">",
"           Cystic fibrosis: Nutritional issues",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/15/19706\">",
"           Cystic fibrosis: Overview of gastrointestinal disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/22/39274\">",
"           Cystic fibrosis: Overview of the treatment of lung disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/62/22503\">",
"           Cystic fibrosis: Prenatal genetic screening",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Interstitial lung disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/22/26985\">",
"           Approach to the infant and child with interstitial lung disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/21/18775\">",
"           Classification of interstitial lung disease in infants and children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/25/21914\">",
"           Clinical manifestations and diagnosis of sarcoidosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/33/43545\">",
"           Genetic disorders of surfactant dysfunction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/51/12089\">",
"           Idiopathic pulmonary hemosiderosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/10/7335\">",
"           Lymphocytic interstitial pneumonitis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/22/360\">",
"           Pulmonary alveolar proteinosis in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Neonatal disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/11/44214\">",
"           Congenital lobar emphysema",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/50/810\">",
"           Congenital pulmonary airway (cystic adenomatoid) malformation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/5/36951\">",
"           Diaphragmatic paralysis in the newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/24/15753\">",
"           Management of bronchopulmonary dysplasia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/51/25398\">",
"           Outcome of infants with bronchopulmonary dysplasia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/49/31511\">",
"           Overview of neonatal respiratory distress: Disorders of transition",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/22/18793\">",
"           Pathogenesis and clinical features of bronchopulmonary dysplasia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/12/19656\">",
"           Pathophysiology and clinical manifestations of respiratory distress syndrome in the newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/37/27225\">",
"           Persistent pulmonary hypertension of the newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/14/27880\">",
"           Prevention of bronchopulmonary dysplasia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/33/4631\">",
"           Pulmonary air leak in the newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/40/17034\">",
"           Pulmonary outcomes of bronchopulmonary dysplasia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/2/32804\">",
"           Transient tachypnea of the newborn",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/38/27241\">",
"           Approach to chest pain in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/1/7193\">",
"           Assessment of the pediatric patient for potential organ donation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/5/34903\">",
"           Atelectasis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/43/16057\">",
"           Causes of bronchiectasis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/39/44662\">",
"           Clinical manifestations and evaluation of bronchiectasis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/58/41895\">",
"           Control of secondhand smoke exposure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/0/37896\">",
"           Hemoptysis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/0/6150\">",
"           Management of bronchiectasis in children without cystic fibrosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/33/41497\">",
"           Management of smoking cessation in adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/18/24874\">",
"           Management of the potential pediatric organ donor",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/31/43513\">",
"           Overview of aerobic exercise testing in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/34/42534\">",
"           Pulmonary manifestations of systemic lupus erythematosus in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/4/5194\">",
"           Secondhand smoke exposure: Effects in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/11/34999\">",
"           Spontaneous pneumomediastinum in children and adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/53/40793\">",
"           Spontaneous pneumothorax in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/26/16810\">",
"           The acute chest syndrome in children and adolescents with sickle cell disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pulmonary function tests",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/27/29112\">",
"           Overview of pulmonary function testing in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pulmonary infection",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/44/16074\">",
"           Bronchiolitis in infants and children: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/19/27962\">",
"           Bronchiolitis in infants and children: Treatment; outcome; and prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/3/38970\">",
"           Clinical features and diagnosis of community-acquired pneumonia in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/55/2938\">",
"           Epidemiology, pathogenesis, and etiology of pneumonia in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/34/9770\">",
"           Epidemiology; clinical presentation; and evaluation of parapneumonic effusion and empyema in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/48/25354\">",
"           Inpatient treatment of pneumonia in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/14/27882\">",
"           Management and prognosis of parapneumonic effusion and empyema in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/0/21512\">",
"           Neonatal pneumonia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/46/27369\">",
"           Outpatient treatment of community-acquired pneumonia in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/11/35001\">",
"           Pneumococcal pneumonia in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/18/33062\">",
"           Pneumonia caused by Chlamydophila (Chlamydia) species in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/56/7050\">",
"           Respiratory syncytial virus infection: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/17/15640\">",
"           Respiratory syncytial virus infection: Prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/27/38327\">",
"           Respiratory syncytial virus infection: Treatment",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Resuscitation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/22/29030\">",
"           Basic airway management in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Sleep",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/50/5929\">",
"           Assessment of sleep disorders in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/60/36806\">",
"           Behavioral sleep problems in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/38/44649\">",
"           Evaluation of suspected obstructive sleep apnea in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/17/40217\">",
"           Management of obstructive sleep apnea in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/36/9801\">",
"           Mechanisms and predisposing factors for sleep related breathing disorders in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/61/15320\">",
"           Medical disorders resulting in problem sleeplessness in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/33/32282\">",
"           Restless legs syndrome and periodic limb movement disorder in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/53/11092\">",
"           Sleep physiology in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/51/28473\">",
"           Sleepwalking and other parasomnias in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Sudden infant death syndrome",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/34/31272\">",
"           Apparent life-threatening event in infants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/20/37194\">",
"           Sudden infant death syndrome: Risk factors and risk reduction strategies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/0/36872\">",
"           Sudden unexpected infant death including SIDS: Initial management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/58/21414\">",
"           Use of home cardiorespiratory monitors in infants",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Trauma",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/63/27640\">",
"           Initial evaluation and stabilization of children with thoracic trauma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/38/29285\">",
"           Pulmonary contusion in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Trauma and injury to the respiratory system",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/46/38632\">",
"           Aspiration due to swallowing dysfunction in infants and children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/13/37081\">",
"           Prevention of smoking initiation in children and adolescents",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Wheezing and cough",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/33/2585\">",
"           Airway foreign bodies in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/9/17561\">",
"           Approach to chronic cough in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/45/30424\">",
"           Approach to wheezing in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/61/21464\">",
"           Assessment of stridor in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/27/28088\">",
"           Causes of chronic cough in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/61/10201\">",
"           Emergent evaluation of acute upper airway obstruction in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/41/1689\">",
"           Wheezing illnesses other than asthma in children",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-E07A990DC8-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f16_14_16608=[""].join("\n");
var outline_f16_14_16608=null;
var title_f16_14_16609="Inlet VSD 4 chamber 2D still frame";
var content_f16_14_16609=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F67011&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F67011&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 580px\">",
"   <div class=\"ttl\">",
"    Inlet VSD 4 chamber 2D still frame",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 560px; height: 440px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This apical four chamber image (inverted) shows the inlet VSD (arrow) at the juncture of the atrioventricular valves. Note that there is no apical displacement of the tricuspid valve hinge point relative to the mitral valve hinge point as is usually seen in normal hearts. With an intact inlet septum, the tricuspid valve is displaced apically when compared with the position of the mitral valve.",
"    <div class=\"footnotes\">",
"     RA: right atrium; LA: left atrium; TV: tricuspid valve; MV: mitral valve; RV: right ventricle; LV: left ventricle; IVS: intraventricular septum; arrow: VSD.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_14_16609=[""].join("\n");
var outline_f16_14_16609=null;
var title_f16_14_16610="Basic effects of electrosurgery";
var content_f16_14_16610=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F62221&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F62221&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Basic effects of electrosurgery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 328px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     Desiccation:",
"    </strong>",
"    Direct contact of the instrument and the tissue causes dehydration and protein denaturation. Continued application of heat with no or minimal tissue penetration results in superficial carbonization (char).",
"    <br>",
"     <strong>",
"      Vaporization:",
"     </strong>",
"     No direct contact, electrode is held at the tissue surface; the high heat generated by the current vaporizes tissue. Since the cells \"explode,\" no char is produced.",
"     <br>",
"      <strong>",
"       Fulguration:",
"      </strong>",
"      No direct contact, electrode is held a bit further away than in vaporization; electrical current (sparks) arcs between the electrode tip and the nearby tissue, which causes it to char.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_14_16610=[""].join("\n");
var outline_f16_14_16610=null;
var title_f16_14_16611="Balantidium microscopy";
var content_f16_14_16611=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F77476&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F77476&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Balantidium microscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 257px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A)",
"    <em>",
"     B. coli",
"    </em>",
"    trophozoite in a Mann's hematoxylin-stained smear, 500x magnification. Note the cytosome (black arrow) and the bean-shaped macronucleus.",
"    <br>",
"     (B)",
"     <em>",
"      B. coli",
"     </em>",
"     trophozoite in a wet mount, 1000x magnification. Note the visible cilia on the cell surface.",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Reproduced from: Centers for Disease Control and Prevention. Parasites and Health: Balantidiasis. Available at:",
"      <a href=\"file://www.dpd.cdc.gov/dpdx/HTML/Balantidiasis.htm\" target=\"_blank\">",
"       file://www.dpd.cdc.gov/dpdx/HTML/Balantidiasis.htm",
"      </a>",
"      .",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_14_16611=[""].join("\n");
var outline_f16_14_16611=null;
var title_f16_14_16612="Vertebral body - transverse section";
var content_f16_14_16612=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F51884&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F51884&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 508px\">",
"   <div class=\"ttl\">",
"    Transverse section of a vertebral body",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 488px; height: 393px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_14_16612=[""].join("\n");
var outline_f16_14_16612=null;
var title_f16_14_16613="Chlorpheniramine and pseudoephedrine: Patient drug information";
var content_f16_14_16613=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Chlorpheniramine and pseudoephedrine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/25/13718?source=see_link\">",
"     see \"Chlorpheniramine and pseudoephedrine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F150160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Dicel&reg; Chewable [OTC];",
"     </li>",
"     <li>",
"      LoHist-D [OTC];",
"     </li>",
"     <li>",
"      Maxichlor PSE [OTC];",
"     </li>",
"     <li>",
"      Neutrahist Pediatric [OTC];",
"     </li>",
"     <li>",
"      SudoGest&trade; Sinus &amp; Allergy [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F150161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Triaminic&reg; Cold &amp; Allergy",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10011438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700543",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before giving this drug to a child. Check all of your child's drugs, including OTC, with doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10011440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691589",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease allergy signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10011439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to chlorpheniramine, pseudoephedrine, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703859",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have taken certain drugs used for low mood (depression) like isocarboxazid, phenelzine, or tranylcypromine or drugs used for Parkinson's disease like selegiline or rasagiline in the last 14 days. Taking this drug within 14 days of those drugs can cause very bad high blood pressure. Talk with your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10011444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697173",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have asthma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697197",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697161",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an enlarged prostate, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697265",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood pressure, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697164",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a bowel block, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697349",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have trouble passing urine, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697564",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit your use of caffeine (for example, tea, coffee, cola) and chocolate. Use with this drug may cause nervousness, shakiness, and a fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4128402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you drink grapefruit juice or eat grapefruit often, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10011445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698279",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nervous and excitable.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698162",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to sleep.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10011447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698625",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure, a fast heartbeat, or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10011442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696039",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is most useful if started before contact with the allergen. Take at least 1 to 3 hours before.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694604",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chewable tablet: Chew or crush well. Mix crushed tablet with food. Do not swallow it whole.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Liquid:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10011443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10011448\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10011449\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12040 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.195.65.247-9CA6F9C4F1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_14_16613=[""].join("\n");
var outline_f16_14_16613=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150160\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150161\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011438\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011440\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011439\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011444\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011445\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011447\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011442\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011443\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011448\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10011449\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?13/25/13718?source=related_link\">",
"      Chlorpheniramine and pseudoephedrine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_14_16614="Mycobacterium bovis";
var content_f16_14_16614=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Mycobacterium bovis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/14/16614/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/14/16614/contributors\">",
"     Elizabeth A Talbot, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/14/16614/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/14/16614/contributors\">",
"     C Fordham von Reyn, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/14/16614/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/14/16614/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/14/16614/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 1, 2009.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Mycobacterium tuberculosis complex includes M. tuberculosis (the cause of most human tuberculosis), M. bovis, M. africanum, and M. microti [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16614/abstract/1\">",
"     1",
"    </a>",
"    ]. Although these are often described as four individual species, they may be considered variants of a single species.",
"   </p>",
"   <p>",
"    M. bovis is the main cause of tuberculosis in cattle, deer, and other mammals. The human bacillus may have arisen from M. bovis in the setting of animal domestication [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16614/abstract/2\">",
"     2",
"    </a>",
"    ]. Human M. bovis infection generally occurs in the setting of consumption of infected cow's milk products, Bacille Calmette-Gu&eacute;rin (BCG) vaccination for TB prevention, or intravesicular BCG installation for bladder cancer treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40136?source=see_link\">",
"     \"BCG vaccination\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The epidemiology, transmission, clinical manifestations, diagnosis and treatment of M. bovis will be reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Worldwide",
"    </span>",
"    &nbsp;&mdash;&nbsp;In developed countries, approximately 1 to 2 percent of human tuberculosis cases are attributable to M. bovis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16614/abstract/3\">",
"     3",
"    </a>",
"    ]. In a review of tuberculosis studies performed around the world between 1954 and 1970, M. bovis was the cause of approximately 2 percent of pulmonary tuberculosis cases; extrapulmonary disease was observed slightly more frequently [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16614/abstract/4\">",
"     4",
"    </a>",
"    ]. At a Spanish university hospital between 1980 and 2003, 0.95 percent of all tuberculosis cases were diagnosed with M. bovis infection [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16614/abstract/5\">",
"     5",
"    </a>",
"    ]. In France, M. bovis infection accounted for 1.6 percent of tuberculosis cases in HIV-positive patients [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16614/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In developing countries, minimal data are available regarding the relative frequency of human disease due to M. bovis given limited laboratory facilities for culture and typing [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16614/abstract/7\">",
"     7",
"    </a>",
"    ]. It is likely to be higher than in developed countries; some have speculated that M. bovis could account for as many as 10 to 15 percent of new human TB cases [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16614/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     United States",
"    </span>",
"    &nbsp;&mdash;&nbsp;Between 1995 and 2005, 1.4 percent (165 of 11,860) US tuberculosis cases were identified as M. bovis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16614/abstract/9\">",
"     9",
"    </a>",
"    ]. Human infection due to M. bovis in the United States has been limited as a result of disease control in cattle herds, slaughterhouse inspection, and routine pasteurization of cow's milk [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16614/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, in the San Diego, California region, the incidence of M. bovis has been noted to be increasing. In a retrospective analysis of tuberculosis case surveillance data in the San Diego region between 1994 and 2005, the incidence of M. bovis increased (from 0.65 to 0.93 per 100,000), while the incidence of M. tuberculosis declined (from 12.1 to 7.33 per 100,000) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16614/abstract/10\">",
"     10",
"    </a>",
"    ]. During this period the annual proportion of culture-positive TB cases attributed to M. bovis increased from 5 to 11 percent. Between 2001 and 2005, M. bovis accounted for 10 percent of cases reported in the San Diego region [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16614/abstract/10\">",
"     10",
"    </a>",
"    ]. In children &lt;15 years of age, M. bovis comprised 54 percent of cases (29 out of 54); in adults &gt;15 years of age, M bovis comprised 8 percent of cases (103 out of 1270). An earlier study of tuberculosis in the San Diego region from 1980 to 1991 described 73 M. bovis cases, which accounted for only about 3 percent of tuberculosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16614/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TRANSMISSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to risk factors for tuberculosis, risk factors for acquisition of M. bovis include consumption of unpasteurized dairy products and contact with infected animals or humans. Among patients diagnosed with tuberculosis, the possibility of M. bovis should be considered in the setting of individuals born in regions where TB is endemic, age &lt;15 years, immunosuppression, HIV infection, and extrapulmonary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16614/abstract/9,11\">",
"     9,11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/13/18649?source=see_link\">",
"     \"Epidemiology of tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Animal to human",
"    </span>",
"    &nbsp;&mdash;&nbsp;Humans may acquire M. bovis by inhaling aerosolized respiratory droplets from infected cattle [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16614/abstract/8\">",
"     8",
"    </a>",
"    ]. M. bovis can also be transmitted to humans by direct contact with other animals such as elk, deer, and seals [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16614/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. An epizootic M. bovis infection in domesticated elk (Cervus elaphus) in Alberta, Canada was recognized in April 1990, when 22 percent of 394 human contacts with elk were noted to have positive tuberculin skin tests; most had known contact with culture-positive animals [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16614/abstract/14\">",
"     14",
"    </a>",
"    ]. A report from Michigan (where M. bovis is known to be endemic in deer) used molecular techniques to confirm transmission of M. bovis from deer to hunters [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16614/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Dairy products",
"    </span>",
"    &nbsp;&mdash;&nbsp;In countries with no cattle tuberculosis control programs, most human cases of M. bovis result from handling or drinking contaminated milk [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16614/abstract/8\">",
"     8",
"    </a>",
"    ]. Less commonly transmission to humans may occur from infected animals via inhalation or contact with mucous membranes and broken skin.",
"   </p>",
"   <p>",
"    In the US and other countries with agriculture control programs, most human cases occur in the setting of contact with imported dairy products made from unpasteurized cow's milk in regions with no control programs. An investigation of 35 cases of human M. bovis disease in New York City between 2001 and 2004, for example, identified fresh cheese from Mexico as the likely source of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16614/abstract/16\">",
"     16",
"    </a>",
"    ]. Cattle sampling at Mexican meat processing plants in 2000 demonstrated M. bovis infection in 17 percent of animals [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16614/abstract/17\">",
"     17",
"    </a>",
"    ]. In addition, an estimated 20 percent of cow's milk products in Mexico destined for production of fresh cheese and similar products are not pasteurized.",
"   </p>",
"   <p>",
"    Of 132 M. bovis tuberculosis cases described in San Diego between 1994 and 2005, &gt;96 percent were found in persons of Hispanic ethnicity, and 60 percent were among those of known Mexican origin [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16614/abstract/10\">",
"     10",
"    </a>",
"    ]. Epidemiologic investigation of the 73 patients from the San Diego review between 1980 to 1991 also demonstrated that 80 percent were of Hispanic origin [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16614/abstract/11\">",
"     11",
"    </a>",
"    ]. Of the non-Hispanic patients, risk factors included: birth in countries with endemic tuberculosis, birth in the United States prior to implementation of M. bovis control, close exposure to individual(s) with known M. bovis exposure, and extensive travel outside the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Meat products",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tuberculosis lesions in the skeletal muscle of infected animals are rare, and heat associated with cooking is sufficient to eliminate risk of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16614/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Human to human",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human transmission of M. bovis infection is relatively rare but can occur in both rural and urban settings, and the interval between infection and overt disease may be short. Nosocomial transmission of multidrug resistant M. bovis has been described, and mortality among HIV-infected persons with multidrug resistant M. bovis may be high [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16614/abstract/19-21\">",
"     19-21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Case reports of human to human M. bovis infection include descriptions of transmission of M. bovis among homeless shelter residents (eg, alcoholics with malnutrition), between siblings on a farm in the United Kingdom, and among social contacts in bars [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16614/abstract/22-28\">",
"     22-28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a cluster of six cases in the UK, for example, one case had high risk contact with cattle and definite consumption of unpasteurized dairy products [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16614/abstract/26\">",
"     26",
"    </a>",
"    ]. All cases were visitors to the same bars where there may have been favorable conditions for transmission (eg, prolonged close contact in a confined space with poor ventilation). All patients had progressive primary disease; four had risk factors predisposing to tuberculosis (eg, HIV infection, diabetes, and use of alcohol and corticosteroids) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16614/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tuberculosis due to M. bovis is clinically and radiographically indistinguishable from tuberculosis due to M. tuberculosis. Like M. tuberculosis, M. bovis can manifest with primary and reactivation forms; involvement may be pulmonary, extrapulmonary, or disseminated. The clinical manifestations, physical examination findings and radiographic abnormalities of tuberculosis are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39673?source=see_link\">",
"     \"Clinical manifestations and evaluation of pulmonary tuberculosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical features associated with M. bovis disease include extrapulmonary disease (with normal chest radiograph) as well as multisite disease (eg both pulmonary and extrapulmonary disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16614/abstract/10,16\">",
"     10,16",
"    </a>",
"    ]. If M. bovis is acquired via the gastrointestinal tract (eg, via ingestion of contaminated diary products), extrapulmonary disease is likelier than the pulmonary manifestations associated with M. tuberculosis. Extrapulmonary sites include involvement of the pleural space, lymph nodes, gastrointestinal tract, peritoneum, genitourinary tract, joints, soft tissue, skin (including chronic forms such as lupus vulgaris), central nervous system and eye [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16614/abstract/5,8,9,16,26,29-32\">",
"     5,8,9,16,26,29-32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prognosis for disease due to M. bovis appears to be worse than for disease due to M. tuberculosis. In a tuberculosis surveillance study including 3291 patients (265 with M. bovis), the relative risk of death due to M. bovis compared to M. tuberculosis was 2.55. In a report of 19 HIV-infected patients with primary multidrug resistant M. bovis, all patients died [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16614/abstract/29,33\">",
"     29,33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation for M. bovis is not a part of routine laboratory testing. Therefore, most patients with M. bovis initially go unrecognized and may respond to shorter duration of therapy for presumed TB. Additional laboratory investigation should be prompted by patients who come to clinical attention in the setting of failure to respond to initial therapy. Susceptibility testing of a mycobacterial isolate with resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/34/31269?source=see_link\">",
"     pyrazinamide",
"    </a>",
"    should also prompt diagnostic testing, as should exposure to other individuals known to have active pulmonary M. bovis infection.",
"   </p>",
"   <p>",
"    The initial approach to diagnosis of M. bovis entails use of the same laboratory tools for diagnosis of M. tuberculosis, including staining for acid-fast bacilli, mycobacterial culture, and PCR testing for mycobacterial DNA. Both the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15924?source=see_link\">",
"     tuberculin skin test",
"    </a>",
"    and the interferon gamma release assay (IGRA) are capable of detecting M. bovis infection, although IGRA performance for detection of active disease has not been fully evaluated and should not be part of the routine diagnostic approach for M. bovis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9098?source=see_link\">",
"     \"Diagnosis of pulmonary tuberculosis in HIV-negative patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Establishing a diagnosis of M. bovis is challenging, particularly because nucleic acid hybridization probe assays cannot be used to distinguish among members of the M. tuberculosis complex. M. bovis is genotypically resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/34/31269?source=see_link\">",
"     pyrazinamide",
"    </a>",
"    (PZA); if monoresistance to PZA is observed in a mycobacterial specimen, the possibility that the etiologic agent is M. bovis rather than M. tuberculosis should be considered. The sensitivity of the pyrazinamide-based case definition is about 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16614/abstract/9\">",
"     9",
"    </a>",
"    ]. However, determination of resistance to PZA is technically difficult and is not performed routinely in many laboratories.",
"   </p>",
"   <p>",
"    Other mechanisms for differentiation of M. bovis from M. tuberculosis include colony morphology, biochemical assays (niacin test, heat-sensitive catalase, nitrate reduction), susceptibility tests (eg, resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/34/31269?source=see_link\">",
"     pyrazinamide",
"    </a>",
"    and susceptibility to the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    analogue thiophen-2-carboxylic acid hydrazide), and PCR genomic analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16614/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For conclusive identification of M. bovis, the isolate should be sent to the state public health laboratory or a mycobacteria reference laboratory. In some cases the isolate is forwarded to the CDC for genotyping.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;M. bovis is inherently resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/34/31269?source=see_link\">",
"     pyrazinamide",
"    </a>",
"    and also likely inherently resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/30/43492?source=see_link\">",
"     cycloserine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16614/abstract/34\">",
"     34",
"    </a>",
"    ]. Acquired resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/9/18583?source=see_link\">",
"     streptomycin",
"    </a>",
"    has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16614/abstract/6,9,10,16,28\">",
"     6,9,10,16,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The approach to treatment of pulmonary and extrapulmonary M. bovis is extrapolated from experience with treatment of M. tuberculosis. Empiric treatment should consist of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    ; subsequent susceptibility testing results should guide individualization of therapy.",
"   </p>",
"   <p>",
"    The duration of therapy for pulmonary and extrapulmonary disease should be nine months; genetic resistance of M. bovis to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/34/31269?source=see_link\">",
"     pyrazinamide",
"    </a>",
"    precludes use of a short-course (6-month) regimen. The regimen consists of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"     isoniazid",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"     ethambutol",
"    </a>",
"    for the first 2 months, followed by 7 months of isoniazid and rifampin [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16614/abstract/28,33,35\">",
"     28,33,35",
"    </a>",
"    ]. The optimal duration for meningitis has not been established; some experts recommend up to 12 months.",
"   </p>",
"   <p>",
"    Details regarding dosing and administration of these agents are as discussed in detail separately for Mycobacterium tuberculosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/21/19802?source=see_link\">",
"     \"Treatment of pulmonary tuberculosis in HIV-negative patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infection control precautions for M. bovis should be followed as for M. tuberculosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16614/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/52/20294?source=see_link\">",
"     \"Tuberculosis transmission and control\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      M bovis is a part of the Mycobacterium tuberculosis complex, which also includes M. tuberculosis. It is the cause of tuberculosis in cattle, and the human bacillus has been postulated to have arisen from M. bovis in the setting of animal domestication. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In developing areas minimal data are available regarding the relative frequency of disease due to M. bovis given limited laboratory facilities for culture and typing. In developed countries, approximately one to two percent of human tuberculosis cases are attributable to M. bovis. In the San Diego, California region, however, the incidence of M. bovis has been noted to be increasing. Between 1980 and 2005 in this region the annual proportion of culture-positive TB cases attributed to M. bovis appears to have increased from 3 to 11 percent. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factors for M. bovis infection include consumption of unpasteurized dairy products and contact with infected animals or humans. Among patients diagnosed with tuberculosis, the possibility of M. bovis should be considered in the setting of foreign born individuals, Hispanic ethnicity, age &lt;15 years, immunosuppression, HIV infection, and extrapulmonary disease. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Transmission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tuberculosis due to M. bovis is clinically and radiographically indistinguishable from tuberculosis due to M. tuberculosis. Like M. tuberculosis, M. bovis can manifest with primary and reactivation forms; involvement may be pulmonary, extrapulmonary, or disseminated. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Establishing a diagnosis of M. bovis is challenging, particularly because nucleic acid hybridization probe assays cannot be used to distinguish among members of the M. tuberculosis complex. M. bovis is genotypically resistant to PZA; if monoresistance to PZA is observed in a mycobacterial specimen, the possibility that the etiologic agent is M. bovis rather than M. tuberculosis should be considered. The state public health laboratories can assist with definitive identification. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that empiric treatment of M. bovis consist of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40279?source=see_link\">",
"       isoniazid",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/7/12406?source=see_link\">",
"       ethambutol",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Genetic resistance to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/34/31269?source=see_link\">",
"       pyrazinamide",
"      </a>",
"      precludes short course therapy. Thus, these drugs are administered for the first 2 months, followed by 7 months of isoniazid and rifampin (daily or twice weekly). Susceptibility testing results should guide individualization of therapy. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Grange, JM, Yates, MD, de Kantor, IN. Guidelines for speciation within the Mycobacterium tuberculosis complex, Second edition, WHO/EMC/ZOO/96.4.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16614/abstract/2\">",
"      Cole ST, Brosch R, Parkhill J, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 1998; 393:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16614/abstract/3\">",
"      O'Reilly LM, Daborn CJ. The epidemiology of Mycobacterium bovis infections in animals and man: a review. Tuber Lung Dis 1995; 76 Suppl 1:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16614/abstract/4\">",
"      Gervois M, Vaillant JM, Fontaine JF, et al. [Epidemiology of the human infection due to Mycobacterium bovis]. Arch Monaldi 1972; 27:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16614/abstract/5\">",
"      Esteban J, Robles P, Soledad Jim&eacute;nez M, Fern&aacute;ndez Guerrero ML. Pleuropulmonary infections caused by Mycobacterium bovis: a re-emerging disease. Clin Microbiol Infect 2005; 11:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16614/abstract/6\">",
"      Dupon M, Ragnaud JM. Tuberculosis in patients infected with human immunodeficiency virus 1. A retrospective multicentre study of 123 cases in France. The Groupe des Infectiologues du Sud de la France. Q J Med 1992; 85:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16614/abstract/7\">",
"      Ayele WY, Neill SD, Zinsstag J, et al. Bovine tuberculosis: an old disease but a new threat to Africa. Int J Tuberc Lung Dis 2004; 8:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16614/abstract/8\">",
"      Cosivi O, Grange JM, Daborn CJ, et al. Zoonotic tuberculosis due to Mycobacterium bovis in developing countries. Emerg Infect Dis 1998; 4:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16614/abstract/9\">",
"      Hlavsa MC, Moonan PK, Cowan LS, et al. Human tuberculosis due to Mycobacterium bovis in the United States, 1995-2005. Clin Infect Dis 2008; 47:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16614/abstract/10\">",
"      Rodwell TC, Moore M, Moser KS, et al. Tuberculosis from Mycobacterium bovis in binational communities, United States. Emerg Infect Dis 2008; 14:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16614/abstract/11\">",
"      Dankner WM, Waecker NJ, Essey MA, et al. Mycobacterium bovis infections in San Diego: a clinicoepidemiologic study of 73 patients and a historical review of a forgotten pathogen. Medicine (Baltimore) 1993; 72:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16614/abstract/12\">",
"      Thompson PJ, Cousins DV, Gow BL, et al. Seals, seal trainers, and mycobacterial infection. Am Rev Respir Dis 1993; 147:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16614/abstract/13\">",
"      Dalovisio JR, Stetter M, Mikota-Wells S. Rhinoceros' rhinorrhea: cause of an outbreak of infection due to airborne Mycobacterium bovis in zookeepers. Clin Infect Dis 1992; 15:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16614/abstract/14\">",
"      Fanning A, Edwards S. Mycobacterium bovis infection in human beings in contact with elk (Cervus elaphus) in Alberta, Canada. Lancet 1991; 338:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16614/abstract/15\">",
"      Wilkins MJ, Meyerson J, Bartlett PC, et al. Human Mycobacterium bovis infection and bovine tuberculosis outbreak, Michigan, 1994-2007. Emerg Infect Dis 2008; 14:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16614/abstract/16\">",
"      Centers for Disease Control and Prevention (CDC). Human tuberculosis caused by Mycobacterium bovis--New York City, 2001-2004. MMWR Morb Mortal Wkly Rep 2005; 54:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16614/abstract/17\">",
"      Mili&aacute;n F, S&aacute;nchez LM, Toledo P, et al. Descriptive study of human and bovine tuberculosis in Quer&eacute;taro, M&eacute;xico. Rev Latinoam Microbiol 2000; 42:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16614/abstract/18\">",
"      Merkal RS, Whipple DL. Inactivation of Mycobacterium bovis in meat products. Appl Environ Microbiol 1980; 40:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16614/abstract/19\">",
"      Rull&aacute;n JV, Herrera D, Cano R, et al. Nosocomial transmission of multidrug-resistant Mycobacterium tuberculosis in Spain. Emerg Infect Dis 1996; 2:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16614/abstract/20\">",
"      Rivero A, M&aacute;rquez M, Santos J, et al. High rate of tuberculosis reinfection during a nosocomial outbreak of multidrug-resistant tuberculosis caused by Mycobacterium bovis strain B. Clin Infect Dis 2001; 32:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16614/abstract/21\">",
"      Bouvet E, Casalino E, Mendoza-Sassi G, et al. A nosocomial outbreak of multidrug-resistant Mycobacterium bovis among HIV-infected patients. A case-control study. AIDS 1993; 7:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16614/abstract/22\">",
"      Grange JM. Mycobacterium bovis infection in human beings. Tuberculosis (Edinb) 2001; 81:71.",
"     </a>",
"    </li>",
"    <li>",
"     LoBue, P. Public significance of Mycobacterium bovis. In: Thoen C, Steele J, Gilsdorf M, eds. Mycobacterium bovis infection in animals and humans. 2nd edn. Oxford, UK: Blackwell, 2006. p. 6.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16614/abstract/24\">",
"      LoBue PA, Betancourt W, Cowan L, et al. Identification of a familial cluster of pulmonary Mycobacterium bovis disease. Int J Tuberc Lung Dis 2004; 8:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16614/abstract/25\">",
"      Velayati AA, Farnia P, Boloorsaze MR, et al. Mycobacterium bovis infection in children in the same family: transmission through inhalation. Monaldi Arch Chest Dis 2007; 67:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16614/abstract/26\">",
"      Evans JT, Smith EG, Banerjee A, et al. Cluster of human tuberculosis caused by Mycobacterium bovis: evidence for person-to-person transmission in the UK. Lancet 2007; 369:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16614/abstract/27\">",
"      Smith RM, Drobniewski F, Gibson A, et al. Mycobacterium bovis infection, United Kingdom. Emerg Infect Dis 2004; 10:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16614/abstract/28\">",
"      O'Donohue WJ Jr, Bedi S, Bittner MJ, Preheim LC. Short-course chemotherapy for pulmonary infection due to Mycobacterium bovis. Arch Intern Med 1985; 145:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16614/abstract/29\">",
"      Guerrero A, Cobo J, Fort&uacute;n J, et al. Nosocomial transmission of Mycobacterium bovis resistant to 11 drugs in people with advanced HIV-1 infection. Lancet 1997; 350:1738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16614/abstract/30\">",
"      Kasambira, TS, Alwood, K, Baker, J, et al. Lymphadenitis in an 18-month-old traveler to Mexico. Pediatr Infect Dis J 2007; 26:968,.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16614/abstract/31\">",
"      Cachafeiro-Vilar A, Garc&iacute;a-Padilla C, Reyes E, Hern&aacute;ndez-Molina G. Polyarticular arthritis secondary to Mycobacterium bovis infection: an unusual clinical presentation. Joint Bone Spine 2007; 74:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16614/abstract/32\">",
"      Liesegang TJ, Cameron JD. Mycobacterium bovis infection of the conjunctiva. Arch Ophthalmol 1980; 98:1764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16614/abstract/33\">",
"      LoBue PA, Moser KS. Treatment of Mycobacterium bovis infected tuberculosis patients: San Diego County, California, United States, 1994-2003. Int J Tuberc Lung Dis 2005; 9:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16614/abstract/34\">",
"      Durek C, R&uuml;sch-Gerdes S, Jocham D, B&ouml;hle A. Sensitivity of BCG to modern antibiotics. Eur Urol 2000; 37 Suppl 1:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16614/abstract/35\">",
"      American Thoracic Society, CDC, Infectious Diseases Society of America. Treatment of tuberculosis. MMWR Recomm Rep 2003; 52:1.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8006 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-CCFD8525CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_14_16614=[""].join("\n");
var outline_f16_14_16614=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Worldwide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      United States",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TRANSMISSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Animal to human",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Dairy products",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Meat products",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Human to human",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40136?source=related_link\">",
"      BCG vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/47/39673?source=related_link\">",
"      Clinical manifestations and evaluation of pulmonary tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9098?source=related_link\">",
"      Diagnosis of pulmonary tuberculosis in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/13/18649?source=related_link\">",
"      Epidemiology of tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/21/19802?source=related_link\">",
"      Treatment of pulmonary tuberculosis in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/52/20294?source=related_link\">",
"      Tuberculosis transmission and control",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_14_16615="Supraventricular arrhythmias after myocardial infarction";
var content_f16_14_16615=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Supraventricular arrhythmias after myocardial infarction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/14/16615/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/14/16615/contributors\">",
"     Philip J Podrid, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/14/16615/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/14/16615/contributors\">",
"     Brian Olshansky, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/14/16615/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/14/16615/contributors\">",
"     James Hoekstra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/14/16615/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/14/16615/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/14/16615/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supraventricular arrhythmias, other than atrial fibrillation or flutter, are relatively uncommon in the periinfarction period. Their occurrence often indicates myocardial dysfunction and they may, by themselves, cause congestive heart failure or exacerbate ongoing myocardial ischemia.",
"   </p>",
"   <p>",
"    The incidence, mechanism, and treatment of supraventricular arrhythmias (particularly sinus bradycardia, sinus tachycardia, and atrial fibrillation) occurring after myocardial infarction (MI) will be reviewed here. The following related topics are discussed separately: conduction disturbances after MI, pathophysiology of ventricular arrhythmias during MI, the clinical characteristics and treatment of ventricular arrhythmias with MI, and risk stratification of patients after MI (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SINUS BRADYCARDIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sinus bradycardia, defined as less than 50 to 60",
"    <span class=\"nowrap\">",
"     beats/min,",
"    </span>",
"    occurs in 15 to 25 percent of patients after acute MI [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16615/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. It has the following clinical characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16615/abstract/1,2,4\">",
"     1,2,4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It is frequently seen with inferior wall infarctions, since the right coronary artery supplies the sinoatrial node (SA) in approximately 60 percent of people.",
"     </li>",
"     <li>",
"      It is most often transient, particularly for sinus bradycardia occurring within the first six hours; such arrhythmias typically resolve within 24 hours.",
"     </li>",
"     <li>",
"      It is usually caused by increased vagal tone, often seen with inferior MI. Other causes include ischemia of the SA node and as a reperfusion arrhythmia following fibrinolysis [",
"      <a class=\"abstract\" href=\"UTD.htm?16/14/16615/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      It is due to medications (beta-blockade).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;If therapy is necessary due to hemodynamic compromise or ischemia, sinus bradycardia following an acute MI usually responds well to intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/23/11640?source=see_link\">",
"     atropine",
"    </a>",
"    (0.6 to 1.0 mg in the majority of cases)&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16615/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Persistent bradycardia with hemodynamic compromise despite intravenous atropine warrants consideration of temporary cardiac pacing [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16615/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Atrial or sequential atrioventricular pacing is superior to ventricular pacing, particularly if there is an associated right ventricular MI [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16615/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Permanent pacing is not typically necessary in patients with sinus bradycardia after an MI, because in most cases the bradyarrhythmia is transient [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16615/abstract/7\">",
"     7",
"    </a>",
"    ]. Any decision to implant a permanent cardiac pacemaker should be delayed for several days of observation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27463?source=see_link\">",
"     \"Indications for permanent cardiac pacing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mortality as a result of periinfarction sinus bradycardia is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16615/abstract/1\">",
"     1",
"    </a>",
"    ]. Its significance is related to the associated reduction in cardiac output and coronary perfusion, thereby exacerbating ischemia, and to the possible development of an escape rhythm with possible AV dissociation causing hemodynamic compromise [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16615/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SINUS TACHYCARDIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sinus tachycardia occurs in approximately 30 to 40 percent of acute myocardial infarctions [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16615/abstract/10\">",
"     10",
"    </a>",
"    ]. Although this is seen soon after the patient arrives in the coronary care unit, the heart rate usually declines over time to a level that reflects the degree of activation of the sympathetic nervous system. Patients with persistent sinus tachycardia usually have larger infarcts that are more often anterior [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16615/abstract/10\">",
"     10",
"    </a>",
"    ] and a marked impairment in left ventricular function, which is associated with substantial morbidity, a high early mortality, and an increased 30-day mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16615/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. In addition, sinus tachycardia may increase the size of ischemic injury and infarction due at least in part to increased oxygen consumption.",
"   </p>",
"   <p>",
"    Therapeutic efforts should be targeted at identification and management of the underlying cause. However, most patients will receive such therapy independent of the tachycardia since early beta blocker administration is part of routine management of acute myocardial infarction. Care should be exercised in the utilization of beta blockers early in an infarction, especially in the presence of large anterior MIs, hypotension, or pulmonary congestion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/53/11098?source=see_link\">",
"     \"Beta blockers in the management of acute coronary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     ATRIAL FIBRILLATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following section will review the incidence, pathophysiology, clinical characteristics, and treatment of the atrial tachyarrhythmias that occur after acute myocardial infarction. Atrial fibrillation is the most common of these.",
"   </p>",
"   <p>",
"    The overall incidence of atrial tachyarrhythmias in the periinfarction period ranges from 6 to 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16615/abstract/9,10,12-17\">",
"     9,10,12-17",
"    </a>",
"    ]. These arrhythmias primarily occur within the first 72 hours after infarction; however, only 3 percent are noted in the very early (less than three-hour) phase [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16615/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Atrial fibrillation (AF) is common both during hospitalization and after discharge for acute MI and in both time periods has prognostic significance. The incidence during hospitalization has been reported to be between 5 and 18 percent and is more likely in individuals with heart failure, kidney disease, hypertension, diabetes, and pulmonary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16615/abstract/13,14,18\">",
"     13,14,18",
"    </a>",
"    ]. As expected with these risk factors, 30-day mortality in patients who develop AF is increased [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16615/abstract/13\">",
"     13",
"    </a>",
"    ]. Long-term mortality is also increased in patients with in-hospital AF compared to those without [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16615/abstract/9,13,15,16,19-22\">",
"     9,13,15,16,19-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Information concerning the longer-term incidence and prognosis of patients who develop AF after discharge comes from the CARISMA study, which evaluated the long-term development of arrhythmias in 271 patients with acute MI and a left ventricular ejection fraction less than 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16615/abstract/18\">",
"     18",
"    </a>",
"    ]. These individuals underwent placement of an implantable loop recorder and were monitored for the development of AF lasting more than 16 beats. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/32/36361?source=see_link&amp;anchor=H8#H8\">",
"     \"Ambulatory monitoring in the assessment of cardiac arrhythmias\", section on 'Implantable loop recorder'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/38/31336?source=see_link&amp;anchor=H11047210#H11047210\">",
"     \"Prophylaxis against ventricular arrhythmias following myocardial infarction\", section on 'Late arrhythmias'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following findings were noted during two years of follow-up:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ninety-five individuals (39 percent) developed AF. Nearly half of these occurred by two months and nearly 80 percent by one year. Most of the AF events were asymptomatic.",
"     </li>",
"     <li>",
"      The duration of the AF event(s) was more than 30 seconds in slightly more than half of these.",
"     </li>",
"     <li>",
"      New onset AF was associated with a significantly increased risk of major cardiovascular events (Unadjusted hazard ratio [HR] 2.04). AF remained a significant predictor of adverse outcomes even after adjustment. The risk was significantly increased in those individuals whose duration of AF was more than 30 seconds (HR 2.73, 95% CI 1.25-5.50), but not in those with episodes lasting less than 30 seconds (HR 1.17, 95% CI 0.35-3.92).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Pathophysiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The increase in the prevalence of AF during an acute MI has been ascribed to one or more of the following factors: atrial dysfunction (due to atrial ischemia, which is rare; infarction, which is rare; or atrial stretching due to heart failure with elevation in left atrial pressures, which is the most common etiology) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16615/abstract/23\">",
"     23",
"    </a>",
"    ], sympathetic stimulation, pericarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16615/abstract/24\">",
"     24",
"    </a>",
"    ], atheromatous disease of the arteries supplying the sinoatrial (SA) and atrioventricular (AV) nodes and the left atrium [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16615/abstract/10,12,21,25\">",
"     10,12,21,25",
"    </a>",
"    ], and iatrogenic factors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6069741\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Statin therapy, possibly due to an antiinflammatory effect, has been associated with a reduction in AF recurrences in patients with lone AF, ischemic heart disease, and after cardiac bypass surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/24/12682?source=see_link&amp;anchor=H30#H30\">",
"     \"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials\", section on 'Statins'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a retrospective study of over 3300 patients presenting with acute myocardial infarction and in sinus rhythm, statin therapy (prescription within 48 hours of hospitalization) was associated with a reduced risk of AF (Odds Ratio 0.64, 95% CI 0.45-0.92) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16615/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, we do not recommend initiation of statin therapy in patients with MI to prevent AF. Almost all such patients should be on statin therapy for other reasons. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33656?source=see_link&amp;anchor=H15#H15\">",
"     \"Cholesterol lowering after an acute coronary syndrome\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of periinfarction atrial tachyarrhythmias is important, because tachycardia can increase myocardial oxygen demand, thereby exacerbating ischemia and possibly decreasing cardiac output. For sustained AF or atrial flutter that is of new onset after the MI and is associated with hemodynamic compromise, we make the following recommendations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initial treatment should consist of rate control. The first-line treatment is beta blockade. &nbsp;",
"     </li>",
"     <li>",
"      For unstable patients, synchronized direct current cardioversion should be considered. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22426?source=see_link\">",
"       \"Restoration of sinus rhythm in atrial fibrillation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22426?source=see_link&amp;anchor=H952132725#H952132725\">",
"       \"Restoration of sinus rhythm in atrial fibrillation\", section on 'Candidates for cardioversion'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      As the onset of the atrial fibrillation associated with MI is usually known (and often less than 48 hours), cardioversion if necessary (within 48 hours) can be performed without the need for three weeks of anticoagulation (but in-hospital anticoagulation is usually recommended as stated below). If the AF is of unknown duration, a transesophageal echocardiogram prior to cardioversion must be performed, if the hemodynamic status allows, and patients should be anticoagulated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      and then",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/39/8825?source=see_link\">",
"       dabigatran",
"      </a>",
"      after cardioversion. (See",
"      <a class=\"local\" href=\"#H446714404\">",
"       'Anticoagulation'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35257?source=see_link\">",
"       \"Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      For episodes of AF with hemodynamic compromise that do not respond to electrical cardioversion or that recur after a brief period of sinus rhythm, the use of intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      to help control rate and help maintain sinus is indicated.",
"      <br/>",
"      <br/>",
"      The use of amiodarone or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      in the setting of hemodynamic compromise is recommended because these drugs are associated with less risk of worsening myocardial dysfunction than some other drugs (although some preparations of intravenous amiodarone can cause hypotension, which is the result of Tween 80, the detergent used to get amiodarone into aqueous solution) and have not been associated with increased risk of mortality post-infarction. However, in many patients hemodynamic compromise during AF is a result of the rapid ventricular rate. In such cases, amiodarone and digoxin, which slow atrioventricular conduction only gradually and after a long period of time, may not be as effective as other agents. We recommend the use of either an intravenous beta blocker or intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      in this setting.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/2/6183?source=see_link\">",
"     Dofetilide",
"    </a>",
"    is also an effective drug for AF after MI to help maintain sinus rhythm. The DIAMOND-MI trial found that this drug had no effect on all-cause, cardiac, or total arrhythmic mortality compared to placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16615/abstract/27\">",
"     27",
"    </a>",
"    ]. However, dofetilide was better than placebo for reverting AF or flutter to sinus rhythm (42.3 versus 12.5 percent for placebo).",
"   </p>",
"   <p>",
"    Patients with sustained AF or atrial flutter with a rapid ventricular response and ongoing ischemia but without hemodynamic compromise should be treated with intravenous beta blockade (this approach is preferred unless contraindicated). One option is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    (2.5 to 5.0 mg every two to five minutes to a total of 15 mg over 10 to 15 minutes).",
"   </p>",
"   <p>",
"    For patients with sustained AF or atrial flutter without ongoing ischemia or hemodynamic compromise, rate control and anticoagulation are indicated. Consideration should be given to cardioversion to sinus rhythm in patients without a history of AF or atrial flutter prior to MI. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12074?source=see_link\">",
"     \"Control of ventricular rate in atrial fibrillation: Pharmacologic therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Long-term antiarrhythmic therapy is generally not necessary if factors associated with recurrent AF, such as moderate to severe left ventricular systolic dysfunction or heart failure, are absent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16615/abstract/16,22,28\">",
"     16,22,28",
"    </a>",
"    ]. We suggest reassessment of the patient&rsquo;s rhythm status in one to two months after MI. If there is no evidence of recurrent AF and if risk factors for recurrence are absent, antiarrhythmic therapy can be discontinued.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H446714404\">",
"    <span class=\"h3\">",
"     Anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal anticoagulation strategy for patients with MI who develop AF for the first time is unknown. Most of our experts recommend the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    in this setting.",
"   </p>",
"   <p>",
"    The guidelines have not addressed the issue of whether patients with acute MI who develop AF need oral anticoagulation prescribed at discharge and if so for how long. There is no consensus among our authors and reviewers as to the optimal approach to anticoagulation in patients with a single episode of AF after MI, especially if the episode is brief (patients with multiple episodes should be managed according to the CHADS2 score). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link&amp;anchor=H31#H31\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some experts suggest anticoagulating all patients with one episode after MI, unless the risk of bleeding is too high. For those patients who are discharged on anticoagulant therapy after one episode of AF, the optimal duration is unknown. As the risk of bleeding is very high in patients on triple antithrombotic therapy, practitioners should carefully and repeatedly reassess the need for continued anticoagulation (and thienopyridine). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/31/13818?source=see_link\">",
"     \"Triple antithrombotic therapy in patients with cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with recurrent episodes of AF or chronic AF (which is often the result of LV dysfunction and heart failure post MI) should be treated with oral anticoagulants. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/60/20425?source=see_link\">",
"     \"Chronic anticoagulation after acute coronary syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PSVT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Paroxysmal supraventricular tachycardia (PSVT) occurs in less than 10 percent of patients after an acute MI, but may require aggressive management due to a rapid ventricular rate [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16615/abstract/29\">",
"     29",
"    </a>",
"    ]. The 2004",
"    <span class=\"nowrap\">",
"     ACC/AHA",
"    </span>",
"    guidelines recommended the following sequence of therapeutic measures for PSVT in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16615/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Carotid sinus massage or a valsalva maneuver (both of which increase vagal tone and alter AV nodal properties). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39481?source=see_link&amp;anchor=H11#H11\">",
"       \"Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias\", section on 'Carotid sinus massage'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Intravenous adenosine (6 mg over one to two seconds; if no response, 12 mg one to two minutes later; may repeat 12 mg dose if needed). We suggest it be used only in patients who have been revascularized.",
"     </li>",
"     <li>",
"      Intravenous beta blockade with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"       metoprolol",
"      </a>",
"      (2.5 to 5.0 mg every two to five minutes to a total of 15 mg over 10 to 15 minutes) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/37/40536?source=see_link\">",
"       esmolol",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       digoxin",
"      </a>",
"      (8 to 15",
"      <span class=\"nowrap\">",
"       microg/kg,",
"      </span>",
"      or 0.6 to 1.0 mg in a patient weighing 70 kg). A delay of at least one hour may occur before the onset of pharmacological effects with digoxin.",
"     </li>",
"     <li>",
"      Our authors and reviewers also suggest that either intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"       amiodarone",
"      </a>",
"      , or cardioversion may be considered.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     NONPAROXYSMAL JUNCTIONAL TACHYCARDIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Junctional tachycardia (or an accelerated junctional tachycardia) is an arrhythmia arising from a discrete focus within the AV node or His bundle. The mechanism is thought to be one of enhanced automaticity rather than reentry. In adults, this rhythm, generally called nonparoxysmal junctional tachycardia, and is an uncommon arrhythmia associated with acute MI [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16615/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. The same arrhythmia may also be seen with digitalis intoxication [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16615/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Atrial activity during junctional tachycardia is variable. Retrograde atrial activation may occur, with a P wave that either follows each QRS complex or is concealed in the QRS complex, as with AVNRT. If retrograde conduction does not occur, independent atrial activity may be seen, with complete AV dissociation that must be distinguished from AV dissociation due to complete heart block (in complete heart block, the atrial rate exceeds the ventricular rate, while with an accelerated junctional tachycardia the atrial rate is slower than the ventricular rate). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39481?source=see_link&amp;anchor=H23#H23\">",
"     \"Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias\", section on 'Undetectable P waves'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nonparoxysmal junctional tachycardia is typically transient, occurring within the first 48 hours of infarction and developing and terminating gradually. No specific antiarrhythmic therapy is indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16615/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H701771643\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Supraventricular arrhythmias, other than atrial fibrillation or flutter, are relatively uncommon in the periinfarction period.",
"     </li>",
"     <li>",
"      The incidence of in-hospital atrial fibrillation after MI ranges from 5 to 18 percent. The development of AF is associated with a worse prognosis.",
"     </li>",
"     <li>",
"      Sinus bradycardia, defined as less than 50 to 60",
"      <span class=\"nowrap\">",
"       beats/min,",
"      </span>",
"      occurs in 15 to 25 percent of patients after acute MI. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Sinus bradycardia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sinus tachycardia occurs in approximately 30 to 40 percent of acute myocardial infarctions. Patients with persistent sinus tachycardia usually have larger infarcts that are more often anterior, associated with a marked impairment in left ventricular function, and a high, early, and 30-day mortality. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Sinus tachycardia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Paroxysmal supraventricular tachycardia (PSVT) occurs in less than 10 percent of patients after an acute MI, but may require aggressive management due to a rapid ventricular rate. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'PSVT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nonparoxysmal junctional tachycardia is typically transient, occurring within the first 48 hours of infarction and developing and terminating gradually. No specific antiarrhythmic therapy is indicated.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16615/abstract/1\">",
"      Marks R, Beard RJ, Clark ML, et al. Gastrointestinal observations in rosacea. Lancet 1967; 1:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16615/abstract/2\">",
"      Adgey AA, Geddes JS, Mulholland HC, et al. Incidence, significance, and management of early bradyarrhythmia complicating acute myocardial infarction. Lancet 1968; 2:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16615/abstract/3\">",
"      Rotman M, Wagner GS, Wallace AG. Bradyarrhythmias in acute myocardial infarction. Circulation 1972; 45:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16615/abstract/4\">",
"      Zimetbaum PJ, Josephson ME. Use of the electrocardiogram in acute myocardial infarction. N Engl J Med 2003; 348:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16615/abstract/5\">",
"      Goldberg S, Greenspon AJ, Urban PL, et al. Reperfusion arrhythmia: a marker of restoration of antegrade flow during intracoronary thrombolysis for acute myocardial infarction. Am Heart J 1983; 105:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16615/abstract/6\">",
"      Zipes DP. The clinical significance of bradycardic rhythms in acute myocardial infarction. Am J Cardiol 1969; 24:814.",
"     </a>",
"    </li>",
"    <li>",
"     Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction. www.acc.org/qualityandscience/clinical/statements.htm (Accessed on August 24, 2006).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16615/abstract/8\">",
"      Topol EJ, Goldschlager N, Ports TA, et al. Hemodynamic benefit of atrial pacing in right ventricular myocardial infarction. Ann Intern Med 1982; 96:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16615/abstract/9\">",
"      Goldberg RJ, Seeley D, Becker RC, et al. Impact of atrial fibrillation on the in-hospital and long-term survival of patients with acute myocardial infarction: a community-wide perspective. Am Heart J 1990; 119:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16615/abstract/10\">",
"      Crimm A, Severance HW Jr, Coffey K, et al. Prognostic significance of isolated sinus tachycardia during first three days of acute myocardial infarction. Am J Med 1984; 76:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16615/abstract/11\">",
"      Becker RC, Burns M, Gore JM, et al. Early assessment and in-hospital management of patients with acute myocardial infarction at increased risk for adverse outcomes: a nationwide perspective of current clinical practice. The National Registry of Myocardial Infarction (NRMI-2) Participants. Am Heart J 1998; 135:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16615/abstract/12\">",
"      JAMES TN. Myocardial infarction and atrial arrhythmias. Circulation 1961; 24:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16615/abstract/13\">",
"      Wong CK, White HD, Wilcox RG, et al. New atrial fibrillation after acute myocardial infarction independently predicts death: the GUSTO-III experience. Am Heart J 2000; 140:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16615/abstract/14\">",
"      Crenshaw BS, Ward SR, Granger CB, et al. Atrial fibrillation in the setting of acute myocardial infarction: the GUSTO-I experience. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries. J Am Coll Cardiol 1997; 30:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16615/abstract/15\">",
"      Pizzetti F, Turazza FM, Franzosi MG, et al. Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction: the GISSI-3 data. Heart 2001; 86:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16615/abstract/16\">",
"      Eldar M, Canetti M, Rotstein Z, et al. Significance of paroxysmal atrial fibrillation complicating acute myocardial infarction in the thrombolytic era. SPRINT and Thrombolytic Survey Groups. Circulation 1998; 97:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16615/abstract/17\">",
"      Schmitt J, Duray G, Gersh BJ, Hohnloser SH. Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. Eur Heart J 2009; 30:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16615/abstract/18\">",
"      Jons C, Jacobsen UG, Joergensen RM, et al. The incidence and prognostic significance of new-onset atrial fibrillation in patients with acute myocardial infarction and left ventricular systolic dysfunction: a CARISMA substudy. Heart Rhythm 2011; 8:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16615/abstract/19\">",
"      Pedersen OD, Bagger H, K&oslash;ber L, Torp-Pedersen C. The occurrence and prognostic significance of atrial fibrillation/-flutter following acute myocardial infarction. TRACE Study group. TRAndolapril Cardiac Evalution. Eur Heart J 1999; 20:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16615/abstract/20\">",
"      Behar S, Zahavi Z, Goldbourt U, Reicher-Reiss H. Long-term prognosis of patients with paroxysmal atrial fibrillation complicating acute myocardial infarction. SPRINT Study Group. Eur Heart J 1992; 13:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16615/abstract/21\">",
"      Hod H, Lew AS, Keltai M, et al. Early atrial fibrillation during evolving myocardial infarction: a consequence of impaired left atrial perfusion. Circulation 1987; 75:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16615/abstract/22\">",
"      Sakata K, Kurihara H, Iwamori K, et al. Clinical and prognostic significance of atrial fibrillation in acute myocardial infarction. Am J Cardiol 1997; 80:1522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16615/abstract/23\">",
"      Celik S, Erd&ouml;l C, Baykan M, et al. Relation between paroxysmal atrial fibrillation and left ventricular diastolic function in patients with acute myocardial infarction. Am J Cardiol 2001; 88:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16615/abstract/24\">",
"      Nagahama Y, Sugiura T, Takehana K, et al. The role of infarction-associated pericarditis on the occurrence of atrial fibrillation. Eur Heart J 1998; 19:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16615/abstract/25\">",
"      Kramer RJ, Zeldis SM, Hamby RI. Atrial fibrillation--a marker for abnormal left ventricular function in coronary heart disease. Br Heart J 1982; 47:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16615/abstract/26\">",
"      Danchin N, Fauchier L, Marijon E, et al. Impact of early statin therapy on development of atrial fibrillation at the acute stage of myocardial infarction: data from the FAST-MI register. Heart 2010; 96:1809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16615/abstract/27\">",
"      K&oslash;ber L, Bloch Thomsen PE, M&oslash;ller M, et al. Effect of dofetilide in patients with recent myocardial infarction and left-ventricular dysfunction: a randomised trial. Lancet 2000; 356:2052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16615/abstract/28\">",
"      Cameron A, Schwartz MJ, Kronmal RA, Kosinski AS. Prevalence and significance of atrial fibrillation in coronary artery disease (CASS Registry). Am J Cardiol 1988; 61:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16615/abstract/29\">",
"      Ganz LI, Friedman PL. Supraventricular tachycardia. N Engl J Med 1995; 332:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16615/abstract/30\">",
"      Konecke LL, Knoebel SB. Nonparoxysmal junctional tachycardia complicating acute myocardial infarction. Circulation 1972; 45:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16615/abstract/31\">",
"      Knoebel SB, Rasmussen S, Lovelace DE, Anderson GJ. Nonparoxysmal junctional tachycardia in acute myocardial infarction: computer-assisted detection. Am J Cardiol 1975; 35:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16615/abstract/32\">",
"      Berisso MZ, Ferroni A, Molini D, Vecchio C. [Supraventricular tachyarrhythmias during acute myocardial infarction: short- and mid-term clinical significance, therapy and prevention of relapse]. G Ital Cardiol 1991; 21:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16615/abstract/33\">",
"      Bigger JT Jr. Digitalis toxicity. J Clin Pharmacol 1985; 25:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16615/abstract/34\">",
"      Kastor JA, Yurchak PM. Recognition of digitalis intoxication in the presence of atrial fibrillation. Ann Intern Med 1967; 67:1045.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 82 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.76.133-2ED5F37753-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_14_16615=[""].join("\n");
var outline_f16_14_16615=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H701771643\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SINUS BRADYCARDIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SINUS TACHYCARDIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      ATRIAL FIBRILLATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6069741\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H446714404\">",
"      - Anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PSVT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      NONPAROXYSMAL JUNCTIONAL TACHYCARDIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H701771643\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/32/36361?source=related_link\">",
"      Ambulatory monitoring in the assessment of cardiac arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/24/12682?source=related_link\">",
"      Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/27/35257?source=related_link\">",
"      Anticoagulation prior to and after restoration of sinus rhythm in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=related_link\">",
"      Antithrombotic therapy to prevent embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/53/11098?source=related_link\">",
"      Beta blockers in the management of acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/55/33656?source=related_link\">",
"      Cholesterol lowering after an acute coronary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/60/20425?source=related_link\">",
"      Chronic anticoagulation after acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/35/39481?source=related_link\">",
"      Clinical manifestations, diagnosis, and evaluation of narrow QRS complex tachycardias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12074?source=related_link\">",
"      Control of ventricular rate in atrial fibrillation: Pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27463?source=related_link\">",
"      Indications for permanent cardiac pacing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/38/31336?source=related_link\">",
"      Prophylaxis against ventricular arrhythmias following myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22426?source=related_link\">",
"      Restoration of sinus rhythm in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/31/13818?source=related_link\">",
"      Triple antithrombotic therapy in patients with cardiovascular disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_14_16616="Epidermolysis bullosa simplex - hands";
var content_f16_14_16616=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F59364%7EDERM%2F73201&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F59364%7EDERM%2F73201&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Epidermolysis bullosa simplex",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bullae are present on the hands of this infant with epidermolysis bullosa simplex.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Epidermolysis bullosa simplex",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple erosions and bullae are present on the foot of this child with epidermolysis bullosa simplex.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_14_16616=[""].join("\n");
var outline_f16_14_16616=null;
var title_f16_14_16617="Diltiazem: Pediatric drug information";
var content_f16_14_16617=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Diltiazem: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"    see \"Diltiazem: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?6/11/6326?source=see_link\">",
"    see \"Diltiazem: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F160657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cardizem&reg;;",
"     </li>",
"     <li>",
"      Cardizem&reg; CD;",
"     </li>",
"     <li>",
"      Cardizem&reg; LA;",
"     </li>",
"     <li>",
"      Cartia XT&reg;;",
"     </li>",
"     <li>",
"      Dilacor XR&reg;;",
"     </li>",
"     <li>",
"      Dilt-CD;",
"     </li>",
"     <li>",
"      Dilt-XR;",
"     </li>",
"     <li>",
"      Diltia XT&reg;;",
"     </li>",
"     <li>",
"      Diltzac;",
"     </li>",
"     <li>",
"      Matzim&reg; LA;",
"     </li>",
"     <li>",
"      Taztia XT&reg;;",
"     </li>",
"     <li>",
"      Tiazac&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F160658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Diltiaz CD&reg;;",
"     </li>",
"     <li>",
"      Apo-Diltiaz SR&reg;;",
"     </li>",
"     <li>",
"      Apo-Diltiaz TZ&reg;;",
"     </li>",
"     <li>",
"      Apo-Diltiaz&reg;;",
"     </li>",
"     <li>",
"      Apo-Diltiaz&reg; Injectable;",
"     </li>",
"     <li>",
"      Ava-Diltiazem;",
"     </li>",
"     <li>",
"      Cardizem&reg; CD;",
"     </li>",
"     <li>",
"      CO Diltiazem CD;",
"     </li>",
"     <li>",
"      CO Diltiazem T;",
"     </li>",
"     <li>",
"      Diltiazem HCl ER&reg;;",
"     </li>",
"     <li>",
"      Diltiazem Hydrochloride Injection;",
"     </li>",
"     <li>",
"      Diltiazem TZ;",
"     </li>",
"     <li>",
"      Diltiazem-CD;",
"     </li>",
"     <li>",
"      Nu-Diltiaz;",
"     </li>",
"     <li>",
"      Nu-Diltiaz-CD;",
"     </li>",
"     <li>",
"      PMS-Diltiazem CD;",
"     </li>",
"     <li>",
"      ratio-Diltiazem CD;",
"     </li>",
"     <li>",
"      Sandoz-Diltiazem CD;",
"     </li>",
"     <li>",
"      Sandoz-Diltiazem T;",
"     </li>",
"     <li>",
"      Teva-Diltiazem;",
"     </li>",
"     <li>",
"      Teva-Diltiazem CD;",
"     </li>",
"     <li>",
"      Teva-Diltiazem HCL ER Capsules;",
"     </li>",
"     <li>",
"      Tiazac&reg;;",
"     </li>",
"     <li>",
"      Tiazac&reg; XC",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1052295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antianginal Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antihypertensive Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Calcium Channel Blocker",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Calcium Channel Blocker, Nondihydropyridine",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1052287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"      see \"Diltiazem: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: Minimal information available; some centers use the following: Initial: 1.5-2 mg/kg/day in 3-4 divided doses (extended release formulations may be dosed once or twice daily); maximum dose: 3.5 mg/kg/day; some centers use a maximum dose of 6 mg/kg/day up to 360 mg/day (Flynn, 2000);",
"     <b>",
"      Note:",
"     </b>",
"     Doses up to 8 mg/kg/day given in 4 divided doses have been used for investigational therapy of Duchenne muscular dystrophy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adolescents &ge;18 years and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Capsule, extended release (once-daily dosing):",
"     <b>",
"      Note:",
"     </b>",
"     Usual dosage range (JNC 7): 180-420 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Cardizem&reg; CD, Cartia XT&reg;, Dilt-CD: Initial: 180-240 mg once daily; may increase dose after 14 days; usual: 240-360 mg once daily; maximum: 480 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Dilacor&reg; XR, Diltia XT&reg;, Dilt-XR: Initial: 180-240 mg once daily; may increase after 14 days; usual: 180-480 mg once daily; maximum: 540 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Taztia XT&reg; Tiazac&reg;: Initial: 120-240 mg once daily; may increase dose after 14 days; maximum: 540 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Capsule, extended release (twice-daily dosing): Initial: 60-120 mg twice daily; may increase dose after 14 days; usual: 240-360 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Diltiazem is available as a generic intended for either once- or twice-daily dosing, depending on the formulation; verify appropriate extended release capsule formulation is administered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Tablet, extended release: Cardizem&reg; LA, Matzim&reg; LA: Initial: 180-240 mg once daily; may increase dose after 14 days; limited clinical experience with doses &gt;360 mg/day; maximum dose: 540 mg once daily; usual dosage range (JNC 7): 120-540 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Tablet, immediate release: 30-120 mg 3-4 times/day; dosage should be increased gradually, at 1- to 2-day intervals until optimum response is obtained; usual maintenance dose: 180-360 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Angina:",
"     </b>",
"     Adults: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Capsule, extended release:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Dilacor XR&reg;, Dilt-XR, Diltia XT&reg;: Initial: 120 mg once daily; titrate over 7-14 days; usual dose range: 120-320 mg/day: maximum: 480 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Cardizem&reg; CD, Cartia XT&reg;, Dilt-CD: Initial: 120-180 mg once daily; titrate over 7-14 days; usual dose range: 120-320 mg/day; maximum: 480 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Tiazac&reg;, Taztia XT&reg;: Initial: 120-180 mg once daily; titrate over 7-14 days; usual dose range: 120-320 mg/day; maximum: 540 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tablet, extended release (Cardizem&reg; LA, Matzim&reg; LA): 180 mg once daily; may increase at 7- to 14-day intervals; usual dose range: 120-320 mg/day; maximum: 360 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tablet, immediate release (Cardizem&reg;): Usual starting dose: 30 mg 4 times/day; titrate dose gradually at 1- to 2-day intervals; usual dose range: 120-320 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Atrial fibrillation, atrial flutter, PSVT:",
"     </b>",
"     Adults: I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Initial bolus dose: 0.25 mg/kg actual body weight over 2 minutes (average adult dose: 20 mg); ACLS guideline recommends 15-20 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Repeat bolus dose (may be administered after 15 minutes if the response is inadequate): 0.35 mg/kg actual body weight over 2 minutes (average adult dose: 25 mg); ACLS guideline recommends 20-25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Continuous infusion (infusions &gt;24 hours or infusion rates &gt;15 mg/hour are not recommended): Initial infusion rate of 10 mg/hour; rate may be increased in 5 mg/hour increments up to 15 mg/hour as needed; some patients may respond to an initial rate of 5 mg/hour.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     If diltiazem injection is administered by continuous infusion for &gt;24 hours, the possibility of decreased diltiazem clearance, prolonged elimination half-life, and increased diltiazem and/or diltiazem metabolite plasma concentrations should be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Conversion from I.V. diltiazem to oral diltiazem:",
"     </b>",
"     Start first oral dose approximately 3 hours after bolus dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Oral dose (mg/day) is approximately equal to [(rate in mg/hour x 3) + 3] x 10;",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Dose per day may need to be divided depending on formulation used",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     3 mg/hour = 120 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     5 mg/hour = 180 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     7 mg/hour = 240 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     11 mg/hour = 360 mg/day (maximum recommended dose)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F160628\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, extended release, oral, as hydrochloride [once-daily dosing]: 120 mg, 180 mg, 240 mg, 300 mg, 360 mg, 420 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardizem&reg; CD: 120 mg, 180 mg, 240 mg, 300 mg, 360 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cartia XT&reg;: 120 mg, 180 mg, 240 mg, 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dilacor XR&reg;: 240 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dilt-CD: 120 mg, 180 mg, 240 mg, 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dilt-XR: 120 mg, 180 mg, 240 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diltia XT&reg;: 120 mg, 180 mg, 240 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diltzac: 120 mg, 180 mg, 240 mg, 300 mg, 360 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Taztia XT&reg;: 120 mg, 180 mg, 240 mg, 300 mg, 360 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tiazac&reg;: 120 mg, 180 mg, 240 mg, 300 mg, 360 mg, 420 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, extended release, oral, as hydrochloride [twice-daily dosing]: 60 mg, 90 mg, 120 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as hydrochloride: 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride: 5 mg/mL (5 mL, 10 mL, 25 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 30 mg, 60 mg, 90 mg, 120 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardizem&reg;: 30 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardizem&reg;: 60 mg, 90 mg, 120 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral, as hydrochloride [once-daily dosing]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardizem&reg; LA: 120 mg, 180 mg, 240 mg, 300 mg, 360 mg, 420 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Matzim&reg; LA: 180 mg, 240 mg, 300 mg, 360 mg, 420 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F160613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1052299\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tablet, immediate release (Cardizem&reg;): Administer before meals and at bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended release preparations (CD, LA, XR, XT, Tiazac): Swallow whole; do not chew, break, or crush. Do not open Dilacor XR&reg; capsules.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dilacor XR&reg;, Dilt-XR, Diltia XT&reg;: Take in the morning on an empty stomach",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardizem&reg; CD, Cardizem&reg; LA, Cartia XT&reg;, Dilt-CD, Matzim&reg; LA: May be administered with or without food, but should be administered consistently with relation to meals; administer with a full glass of water",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Taztia XT&reg; and Tiazac&reg; capsules (extended release) may be opened and sprinkled on applesauce; swallow applesauce immediately, do not chew; follow with some cool water (adults: 1 glass) to ensure complete swallowing; do not use hot applesauce; do not divide capsule contents (ie, do not administer partial doses); do not store mixture of applesauce and capsule contents, use immediately",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V. bolus: Adults: Infuse over 2 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V. continuous infusion: May dilute with NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, or D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS; maximum final concentration: 1 mg/mL",
"    </p>",
"   </div>",
"   <div class=\"block uicp drugH1Div\" id=\"F14471310\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     1 mg/mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F160718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Albumin, alcohol (ethyl), amiodarone, amikacin, amphotericin B (conventional), argatroban, aztreonam, bivalirudin, bumetanide, caspofungin, cefazolin, cefotaxime, cefotetan, cefoxitin, ceftazidime, ceftriaxone, cefuroxime, cimetidine, ciprofloxacin, clindamycin, dexmedetomidine, digoxin, dobutamine, dopamine, doripenem, doxycycline, epinephrine, erythromycin lactobionate, esmolol, fenoldopam, fentanyl, fluconazole, gentamicin, hetastarch in lactated electrolyte injection (Hextend&reg;), hydromorphone, imipenem/cilastatin, labetalol, lidocaine, lorazepam, meperidine, metoclopramide, metronidazole, midazolam, milrinone, morphine, multivitamins, nesiritide, nicardipine, nitroglycerin, nitroprusside, norepinephrine, oxacillin, pancuronium, penicillin G potassium, pentamidine, piperacillin, potassium chloride, potassium phosphates, ranitidine, sulfamethoxazole/trimethoprim, telavancin, terbutaline, theophylline, ticarcillin/clavulanate potassium, tobramycin, vancomycin, vasopressin, vecuronium.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Diazepam, furosemide, micafungin, phenytoin, rifampin, thiopental.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Acetazolamide, acyclovir, aminophylline, ampicillin, ampicillin/sulbactam, heparin, hydrocortisone sodium succinate, insulin (regular), methylprednisolone sodium succinate, metoprolol, nafcillin, procainamide, sodium bicarbonate, tenecteplase.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Ceftriaxone.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1052290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Dispense oral formulations in a tight, light-resistant container; avoid excess humidity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Capsule: Extended release:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cardizem&reg; CD, Tiazac&reg;: Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C  to 30&deg;C (59&deg;F to 86&deg;F).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cartia XT&reg;, Dilacor XR&reg; Dilt-CD, Diltia XT&reg;, Taztia XT&reg;: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Dilt-XR: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Tablet: Immediate release:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cardizem: Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Diltiazem: Store at  20&deg;C to 25&deg;C (68&deg;F to 77&deg;F).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Tablet: Extended release:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Cardizem LA: Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     Matzim&reg; LA: Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); avoid temperatures above 30&deg;C (86&deg;F).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection: Store vials under refrigeration at 2&ordm;C to 8&ordm;C (36&ordm;F to 46&ordm;F); do not freeze. Contains no preservatives, discard unused portion. May store unopened at room temperature for up to 1 month; destroy after 1 month at room temperature. Compatible in D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS, and D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS at a maximum concentration of 1 mg/mL for 24 hours when stored at room temperature or under refrigeration. Do not mix with other drugs in the same container; do not coinfuse with other drugs in the same I.V. line;",
"     <b>",
"      not",
"     </b>",
"     physically compatible with acetazolamide, acyclovir, aminophylline, ampicillin, ampicillin and sulbactam, cefamandole, cefoperazone,  diazepam, furosemide, hydrocortisone, insulin, methylprednisolone, mezlocillin,  nafcillin, phenytoin, rifampin, and sodium bicarbonate.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1052298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Treatment of chronic stable angina or angina from coronary artery spasm; hypertension (",
"     <b>",
"      Note:",
"     </b>",
"     Only extended release products are FDA approved for the treatment of hypertension) (FDA approved in adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection: Management of atrial fibrillation or atrial flutter; paroxysmal supraventricular tachycardias (PSVT) (FDA approved in adults); has also been used for stable narrow-complex tachycardia uncontrolled or unconverted by adenosine or vagal maneuvers or if SVT is recurrent",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F160720\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cardizem&reg; may be confused with Cardene&reg;, Cardene SR&reg;, Cardizem CD&reg;, Cardizem SR&reg;, cortisone",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cartia XT&reg; may be confused with Procardia XL&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Diltiazem may be confused with Calan&reg;, diazepam, Dilantin&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Tiazac&reg; may be confused with Tigan&reg;, Tiazac&reg; XC [CAN], Ziac&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication (I.V. formulation) among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Significant differences exist between oral and I.V. dosing. Use caution when converting from one route of administration to another.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cardizem [U.S., Canada, and multiple international markets] may be confused with Cardem brand name for celiprolol [Spain]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cartia XT [U.S.] may be confused with Cartia brand name for aspirin [multiple international markets]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Dilacor XR [U.S.]  may be confused with Dilacor brand name for verapamil [Brazil]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Dipen [Greece] may be confused with Depen brand name for penicillamine [U.S.]; Depin brand name for nifedipine [India]; Depon brand name for acetaminophen [Greece]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Tiazac: Brand name for diltiazem [U.S, Canada], but also the brand name for pioglitazone [Chile]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F160717\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Cardiovascular: AV block, bradycardia, edema, extrasystoles, flushing, hypotension, pain, palpitation, vasodilation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Dizziness, headache, nervousness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Gout",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, diarrhea, dyspepsia, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site reactions: Burning, itching",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myalgia, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchitis, dyspnea, pharyngitis, rhinitis sinus congestion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Alkaline phosphatase increased, allergic reaction, ALT increased, AST increased, amblyopia, amnesia, arrhythmia, AV block (second or third degree), bundle branch block, CHF, depression, dysgeusia, extrapyramidal symptoms, gingival hyperplasia, hemolytic anemia, petechiae, photosensitivity, Stevens-Johnson syndrome, syncope, tachycardia, thrombocytopenia, tremor, toxic epidermal necrolysis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1052304\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to diltiazem or any component; severe hypotension; second or third degree heart block (except in patients with a functioning artificial pacemaker); sick-sinus syndrome (except in patients with a functioning artificial pacemaker); acute MI with pulmonary congestion; cardiogenic shock; I.V. administration concomitantly or within a few hours of the administration of I.V. beta-blockers; atrial fibrillation or flutter associated with accessory bypass tract (eg, Wolff-Parkinson-White syndrome or short PR syndrome); ventricular tachycardia (with wide-complex tachycardia, must determine whether origin is supraventricular or ventricular)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1052286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with CHF or impaired renal or hepatic function. Dermatologic reactions may occur; these may be transient or disappear with continued therapy; however, erythema multiforme or exfoliative dermatitis have been reported; discontinue diltiazem if skin rash persists or is severe. Use Dilacor&reg; XR with caution in patients with pre-existing severe GI narrowing; this product uses a slowly disintegrating matrix;",
"     <b>",
"      Note:",
"     </b>",
"     No reports of obstructive symptoms in patients with strictures have been reported, but caution is advised.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1052285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause bradycardia, second or third degree heart block, hypotension, or rarely, acute hepatic injury (with significant elevations in hepatic transaminases); may worsen CHF. The risk of first-, second-, or third-degree heart block or sinus bradycardia is increased when used with agents that slow cardiac conduction. Concomitant  use of diltiazem and a beta-blocker may result in conduction disturbances, hypotension, and worsened LV function. Use with other agents known to either reduce SA node function and/or AV nodal conduction (eg, digoxin) or reduce sympathetic outflow (eg, clonidine) may  increase the risk of serious bradycardia.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F160705\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C9 (minor), CYP2D6 (minor), CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C9 (weak), CYP2D6 (weak), CYP3A4 (moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F160622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfentanil: Diltiazem may increase the serum concentration of Alfentanil.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: Calcium Channel Blockers (Nondihydropyridine) may enhance the bradycardic effect of Amiodarone. Sinus arrest has been reported.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anilidopiperidine Opioids: May enhance the bradycardic effect of Calcium Channel Blockers (Nondihydropyridine). Anilidopiperidine Opioids may enhance the hypotensive effect of Calcium Channel Blockers (Nondihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically, itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Calcium Channel Blockers. Management: Concurrent use of felodipine or nisoldipine with itraconazole is specifically contraindicated.  Frequent monitoring is warranted with any such combination; calcium channel blocker dose reductions may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May increase the serum concentration of Diltiazem. Diltiazem may increase the serum concentration of Aprepitant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtorvaSTATin: May increase the serum concentration of Diltiazem. Diltiazem may increase the serum concentration of AtorvaSTATin. Management: Consider using lower atorvastatin doses when used together with diltiazem.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atosiban: Calcium Channel Blockers may enhance the adverse/toxic effect of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avanafil.  Management: The maximum avanafil adult dose is 50 mg per 24-hour period when used together with a moderate CYP3A4 inhibitor.  Patients receiving such a combination should also be monitored more closely for evidence of adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Calcium Channel Blockers. Management: Monitor for decreased therapeutic effects of calcium channel blockers with concomitant barbiturate therapy. Calcium channel blocker dose adjustments may be necessary. Nimodipine Canadian labeling contraindicates concomitant use with phenobarbital.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Calcium Channel Blockers (Nondihydropyridine) may decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Calcium Channel Blockers (Nondihydropyridine) may enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BusPIRone: Calcium Channel Blockers (Nondihydropyridine) may decrease the metabolism of BusPIRone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Dihydropyridine): May enhance the hypotensive effect of Calcium Channel Blockers (Nondihydropyridine). Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May diminish the therapeutic effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May decrease the serum concentration of Calcium Channel Blockers (Nondihydropyridine). Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of CarBAMazepine. Management: Consider empiric reductions in carbamazepine dose with initiation of nondihydropyridine calcium channel blockers. Monitor for increased toxic effects of carbamazepine and reduced therapeutic effects of the calcium channel blocker.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Calcium Channel Blockers (Nondihydropyridine) may enhance the AV-blocking effect of Cardiac Glycosides. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May increase the serum concentration of Calcium Channel Blockers. Management: Consider alternatives to cimetidine. If no suitable alternative exists, monitor for increased effects of calcium channel blockers following cimetidine initiation/dose increase, and decreased effects following cimetidine discontinuation/dose decrease.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloNIDine: May enhance the AV-blocking effect of Calcium Channel Blockers (Nondihydropyridine). Sinus node dysfunction may also be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: Calcium Channel Blockers may diminish the therapeutic effect of Clopidogrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.  Management: Reduce colchicine dose as directed when using with a moderate CYP3A4 inhibitor, and increase monitoring for colchicine-related toxicity.  Use extra caution in patients with impaired renal and/or hepatic function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colestipol: May decrease the absorption of Diltiazem.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Calcium Channel Blockers (Nondihydropyridine) may decrease the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May decrease the metabolism of Calcium Channel Blockers (Nondihydropyridine). Calcium Channel Blockers (Nondihydropyridine) may decrease the metabolism of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dantrolene: May enhance the hyperkalemic effect of Calcium Channel Blockers (Nondihydropyridine). Dantrolene may enhance the negative inotropic effect of Calcium Channel Blockers (Nondihydropyridine). Management: This interaction has only been described with intravenous dantrolene administration.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: Calcium Channel Blockers (Nondihydropyridine) may enhance the AV-blocking effect of Dronedarone. Other electrophysiologic effects of Dronedarone may also be increased. Dronedarone may increase the serum concentration of Calcium Channel Blockers (Nondihydropyridine). Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Dronedarone.  Management: Use lower starting doses of the nondihydropyridine calcium channel blockers (i.e., verapamil, diltiazem), and only consider increasing calcium channel blocker dose after obtaining ECG-based evidence that the combination is being well-tolerated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eletriptan: Calcium Channel Blockers (Nondihydropyridine) may decrease the metabolism of Eletriptan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Calcium Channel Blockers (Nondihydropyridine) may decrease the metabolism of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: Diltiazem may enhance the bradycardic effect of Fingolimod.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: Diltiazem may increase the serum concentration of Fosaprepitant. Specifically, diltiazem may increase the concentration of the active metabolite aprepitant. Fosaprepitant may increase the serum concentration of Diltiazem. The active metabolite aprepitant is likely responsible for this effect.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Calcium Channel Blockers may increase the serum concentration of Fosphenytoin.  Management: Monitor for phenytoin toxicity with concomitant use of a calcium channel blocker (CCB) or decreased phenytoin effects with CCB discontinuation. Monitor for decreased CCB therapeutic effects. Nimodipine Canadian labeling contraindicates use with phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May increase the serum concentration of Diltiazem.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: Calcium Channel Blockers (Nondihydropyridine) may enhance the bradycardic effect of Ivabradine. Ivabradine may enhance the QTc-prolonging effect of Calcium Channel Blockers (Nondihydropyridine). Specifically, the QTc prolonging effects of bepridil may be enhanced. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Ivabradine. Specifically, verapamil or diltiazem may increase serum ivabradine concentrations.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg daily in patients also receiving moderate CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Calcium Channel Blockers (Nondihydropyridine) may enhance the neurotoxic effect of Lithium. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Lithium. Decreased or unaltered lithium concentrations have also been reported with this combination.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: Diltiazem may increase the serum concentration of Lovastatin. Lovastatin may increase the serum concentration of Diltiazem.  Management: Initiate lovastatin at a maximum adult dose of 10 mg/day, and do not exceed 20 mg/day, in patients receiving diltiazem. Monitor closely for signs of HMG-CoA reductase inhibitor toxicity (e.g., myositis, rhabdomyolysis).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lurasidone.  Management: U.S. labeling: start at 20 mg/day and limit to max of 80 mg/day with moderate CYP3A4 inhibitor.  Canadian labeling: limit to max of 40 mg/day with moderate CYP3A4 inhibitor; avoid concomitant use of grapefruit products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Calcium Channel Blockers. Management: Consider using a noninteracting macrolide. Monitor for increased therapeutic effects of calcium channel blockers if an interacting macrolide antibiotic is initiated, or decreased effects if a macrolide is discontinued.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Salts: Calcium Channel Blockers may enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypotensive effect of Antihypertensives. MAO Inhibitors may enhance the orthostatic hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midodrine: Calcium Channel Blockers (Nondihydropyridine) may enhance the bradycardic effect of Midodrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nafcillin: May increase the metabolism of Calcium Channel Blockers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents (Nondepolarizing): Calcium Channel Blockers may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nitroprusside: Calcium Channel Blockers may enhance the hypotensive effect of Nitroprusside.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Calcium Channel Blockers may increase the serum concentration of Phenytoin.  Management: Monitor for phenytoin toxicity with concomitant use of a calcium channel blocker (CCB) or decreased phenytoin effects with CCB discontinuation. Monitor for decreased CCB therapeutic effects. Nimodipine Canadian labeling contraindicates use with phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May decrease the metabolism of Calcium Channel Blockers (Nondihydropyridine). Increased serum concentrations of the calcium channel blocker may increase risk of AV nodal blockade. Management: Avoid concurrent use when possible. If this combination is used, monitor for evidence of toxicity. The manufacturer of atazanavir recommends a 50% dose reduction for diltiazem be considered. Saquinavir or tipranavir use with bepridil is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Diltiazem may increase the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Ranolazine.  Management: Limit ranolazine dose to a maximum of 500 mg twice daily when used with diltiazem or verapamil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Red Yeast Rice: Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Red Yeast Rice. Specifically, concentrations of lovastatin (and possibly other related compounds) may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers. Management: The labeling for some U.S. and Canadian calcium channel blockers contraindicate use with rifampin however recommendations vary. Consult appropriate labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Diltiazem may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Calcium Channel Blockers (Nondihydropyridine) may enhance the anticoagulant effect of Salicylates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: Diltiazem may increase the serum concentration of Simvastatin. Simvastatin may increase the serum concentration of Diltiazem.  Management: Avoid concurrent use of diltiazem with simvastatin when possible.  If used together, limit adult maximum simvastatin dose to 10 mg/day, and avoid Simcor (simvastatin/niacin) because fixed simvastatin doses in the product exceed this maximum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Calcium Channel Blockers (Nondihydropyridine) may decrease the metabolism of Tacrolimus (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): Calcium Channel Blockers (Nondihydropyridine) may decrease the metabolism of Tacrolimus (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vilazodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vilazodone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zuclopenthixol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1052307\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A high-fat meal does not affect extent of absorption of Cardizem&reg; CD, Cardizem&reg; LA, Cartia XT&reg;, Matzim&reg; LA, Taztia XT&reg;, or Tiazac&reg;, but peak serum concentrations for Taztia XT&reg; and Tiazac&reg; may occur slightly earlier. Administration of Diltia XT&reg; or Dilacor&reg; XR with a high-fat meal may increase extent of absorption and peak concentration. Avoid natural licorice (causes sodium and water retention and increases potassium loss).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F160624\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F160639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic and embryotoxic effects have been demonstrated in animal reproduction studies.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1052294\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure, heart rate, renal function, liver enzymes; ECG with I.V. therapy",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1052284\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits calcium ions from entering the &ldquo;slow channels&rdquo; or select voltage-sensitive areas of vascular smooth muscle and myocardium during depolarization; produces a relaxation of coronary vascular smooth muscle and coronary vasodilation; increases myocardial oxygen delivery in patients with vasospastic angina",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1052302\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Tablet: Immediate release: 30-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Parenteral (I.V. bolus): Within 3 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Maximum effect:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Antiarrhythmic (I.V. bolus): 2-7 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Antihypertensive (Oral; multiple dosing): Within 2 weeks",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1052303\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: 80%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 1.7 L/kg; appears in breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 70% to 80%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensive first-pass effect; metabolized in the liver; desacetyldiltiazem is an active metabolite (25% to 50% as potent as diltiazem based on coronary vasodilation effects); desacetyldiltiazem may accumulate with plasma concentrations 10% to 20% of diltiazem levels",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: &sim;40%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 3-4.5 hours, up to 8 hours with chronic high dosing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tablet: Immediate release: 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardizem&reg; CD: 10-14 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardizem&reg; LA, Matzim&reg; LA: 11-18 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardizem&reg; SR: 6-11 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dilacor&reg; XR: 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: In urine and bile mostly as metabolites; 2% to 4% excreted as unchanged drug in urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Not dialyzable",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1052292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?6/11/6326?source=see_link\">",
"      see \"Diltiazem: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not crush, break, or chew extended release form. Do not discontinue abruptly; report any dizziness, shortness of breath, palpitations, or edema; avoid alcohol. May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; contact physician if reaction occurs.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1052305\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cartia XT&reg; and Dilt CD are the generic versions of Cardizem&reg; CD; Diltia XT&reg; and Dilt-XR are the generic versions of Dilacor XR&reg;; Taztia XT&reg; is the generic version of Tiazac&reg;; Matzim&reg; LA is the generic version of  Cardizem&reg; LA.",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F160634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 12 mg/mL oral suspension may be made from tablets (regular, not extended release) and one of three different vehicles (cherry syrup, a 1:1 mixture of Ora-Sweet&reg; and Ora-Plus&reg;, or a 1:1 mixture of Ora-Sweet&reg; SF and Ora-Plus&reg;). Crush sixteen 90 mg tablets in a mortar and reduce to a fine powder. Add 10 mL of the chosen vehicle and mix to a uniform paste; mix while adding the vehicle in incremental proportions to",
"     <b>",
"      almost",
"     </b>",
"     120 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 120 mL. Label &ldquo;shake well&rdquo; and &ldquo;protect from light\". Stable for 60 days when stored in amber plastic prescription bottles in the dark at room temperature or refrigerated.",
"    </p>",
"    <div class=\"reference\">",
"     Allen LV and Erickson MA, &ldquo;Stability of Baclofen, Captopril, Diltiazem Hydrochloride, Dipyridamole, and Flecainide Acetate in Extemporaneously Compounded Oral Liquids,&rdquo;",
"     <i>",
"      Am J Health Syst Pharm",
"     </i>",
"     , 1996, 53(18):2179-84.",
"     <span class=\"pubmed-id\">",
"      8879325",
"     </span>",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Bertorini TE, Palmieri GMA, Griffin JW, et al, &ldquo;Effect of Chronic Treatment With the Calcium Antagonist Diltiazem in Duchenne Muscular Dystrophy,&rdquo;",
"      <i>",
"       Neurology",
"      </i>",
"      , 1988, 38(4):609-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/14/16617/abstract-text/3281058 /pubmed\" id=\"3281058 \" target=\"_blank\">",
"        3281058",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/14/16617/abstract-text/12748199 /pubmed\" id=\"12748199 \" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Field JM, Hazinski MF, Sayre MR, et al, \"Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):640-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/14/16617/abstract-text/20956217/pubmed\" id=\"20956217\" target=\"_blank\">",
"        20956217",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Flynn JT and Pasko DA, &ldquo;Calcium Channel Blockers: Pharmacology and Place in Therapy of Pediatric Hypertension,&rdquo;",
"      <i>",
"       Pediatr Nephrol",
"      </i>",
"      , 2000, 15(3-4):302-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/14/16617/abstract-text/11149130/pubmed\" id=\"11149130\" target=\"_blank\">",
"        11149130",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Neumar RW, Otto CW, Link MS, et al, \"Part 8: Adult Advanced Cardiovascular Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):729-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/14/16617/abstract-text/20956/pubmed\" id=\"20956\" target=\"_blank\">",
"        20956",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pass RH, Liberman L, Al-Fayaddh M, et al, \"Continuous Intravenous Diltiazem Infusion for Short-Term Ventricular Rate Control in Children,\"",
"      <i>",
"       Am J Cardiol",
"      </i>",
"      , 2000, 86(5):559-62, A9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?16/14/16617/abstract-text/11009280/pubmed\" id=\"11009280\" target=\"_blank\">",
"        11009280",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13233 Version 50.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.172.26-C9598D4138-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_14_16617=[""].join("\n");
var outline_f16_14_16617=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160657\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160658\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052295\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052287\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160628\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160613\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052299\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14471310\">",
"      Usual Infusion Concentrations: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160718\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052290\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052298\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160720\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160717\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052304\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052286\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052285\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160705\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160622\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052307\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160624\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160639\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052294\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052284\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052302\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052303\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052292\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1052305\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F160634\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13233\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13233|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=related_link\">",
"      Diltiazem: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?6/11/6326?source=related_link\">",
"      Diltiazem: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_14_16618="Familial adenomatous polyposis and MUTYH associated polyposis: Screening and management of patients and families";
var content_f16_14_16618=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Familial adenomatous polyposis and MUTYH associated polyposis: Screening and management of patients and families",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/14/16618/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/14/16618/contributors\">",
"     Peter A L Bonis, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/14/16618/contributors\">",
"     Dennis J Ahnen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/14/16618/contributors\">",
"     Lisen Axell, MS, CGC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/14/16618/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/14/16618/contributors\">",
"     J Thomas LaMont, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/14/16618/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?16/14/16618/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?16/14/16618/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?16/14/16618/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical features that raise the suspicion of a familial form of cancer susceptibility in a patient diagnosed with any type of malignancy include [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A cancer that occurs at an unusually young age compared with its usual presentation",
"     </li>",
"     <li>",
"      The development of multiple tumors in a single organ, or bilateral development of tumors in paired organs",
"     </li>",
"     <li>",
"      The development of more than one primary tumor of any type",
"     </li>",
"     <li>",
"      A family history of cancer of the same type or related type in one or more first-degree relatives",
"     </li>",
"     <li>",
"      A high rate of cancer occurrence in the family",
"     </li>",
"     <li>",
"      Cancer occurring in an individual or within a family with congenital anomalies or birth defects",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The genetics underlying an inherited predisposition to cancer are rapidly being uncovered and current data permit routine use of molecular tools to diagnose some of these disorders, as well as interventions to prevent the development of cancer. A searchable online catalog of cancer family syndromes published through the National Center for Biotechnology Information is available online at:",
"    <a class=\"external\" href=\"file://www.ncbi.nlm.nih.gov/omim\">",
"     www.ncbi.nlm.nih.gov/omim",
"    </a>",
"    . A concise handbook has also been published [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among the multiple cancer family syndromes, several are known to be associated with the development of colon cancer, including adenomatous and hamartomatous polyposis syndromes (eg, familial adenomatous polyposis, MUTYH associated polyposis, juvenile polyposis, Peutz-Jeghers syndrome) and Lynch syndrome. These disorders may be diagnosed during evaluation of an individual patient or during screening of family members who are known to be at risk. Although the effectiveness of screening and surveillance strategies for these syndromes is largely unproven by controlled clinical trials, the high cancer risk warrants screening, and reasonable recommendations have been made. For those disorders for which genetic testing is available, a list of testing laboratories can be obtained through the Genetic Testing Resource (",
"    <a class=\"external\" href=\"file://www.genetests.org/\">",
"     www.genetests.org",
"    </a>",
"    ). A listing of national genetic counselors is available at",
"    <a class=\"external\" href=\"file://www.nsgc.org/\">",
"     www.nsgc.org",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    This topic review will discuss the recommendations for screening and surveillance of index patients and their families with familial adenomatous polyposis (FAP) and MUTYH associated polyposis (MAP). The diagnosis of FAP, the management of patients and families with other hereditary colon cancer syndromes, screening strategies in patients with a family history of colorectal cancer or colonic polyps who are not known to have one of the above conditions, and screening strategies in patients at average risk for colorectal cancer are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17016?source=see_link\">",
"     \"Clinical manifestations and diagnosis of familial adenomatous polyposis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37034?source=see_link\">",
"     \"Screening for colorectal cancer: Strategies in patients at average risk\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/41/9881?source=see_link\">",
"     \"Screening for colorectal cancer: Strategies in patients with possible increased risk due to family history\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/5/29783?source=see_link\">",
"     \"Lynch syndrome (hereditary nonpolyposis colorectal cancer): Screening and management of patients and families\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/9/3224?source=see_link\">",
"     \"Peutz-Jeghers syndrome and juvenile polyposis: Screening and management of patients and families\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several other genetic syndromes are associated with gastrointestinal polyposis. The risk of colon cancer in some of these diseases is uncertain, and may not be increased. Examples include Cowden and Bannayan-Riley-Ruvalcaba syndromes (both part of the PTEN hamartoma tumor syndrome), intestinal ganglioneuromatosis, Devon family syndrome, and Cronkhite-Canada syndrome. These rare disorders will not be discussed in this topic review. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29530?source=see_link\">",
"     \"PTEN hamartoma tumor syndrome, including Cowden syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     FAMILIAL ADENOMATOUS POLYPOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial adenomatous polyposis (FAP) is an autosomal dominant disease caused by mutations in the adenomatous polyposis coli (",
"    <em>",
"     APC",
"    </em>",
"    ) gene, which is located on chromosome 5q21-q22. FAP occurs in approximately 1 out of 10,000 to 1 out of 30,000 live births, and accounts for less than 1 percent of the total colon cancer risk in the United States. Genetic testing for FAP is routinely available and is the basis for the diagnosis of the disease in patients with polyposis and for genetic screening of at-risk family members. (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17016?source=see_link\">",
"     \"Clinical manifestations and diagnosis of familial adenomatous polyposis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/33/30234?source=see_link\">",
"     \"Molecular genetics of colorectal cancer\"",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    It is generally agreed that a definitive clinical diagnosis of FAP should be entertained in any individual with more than 100 lifetime adenomas, with the caveats that attenuated forms of FAP can present with a much lower adenoma burden and that some patients with MUTYH associated polyposis (MAP) can have more than 100 adenomas. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Attenuated FAP'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H18\">",
"     'MUTYH associated polyposis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    With routine testing, about 10 to 30 percent of patients who meet the criteria for classic FAP do not have a detectable",
"    <em>",
"     APC",
"    </em>",
"    mutation and as many as 90 percent of patients with attenuated FAP do not have a detectable",
"    <em>",
"     APC",
"    </em>",
"    mutation [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/2\">",
"     2",
"    </a>",
"    ]. Some of these patients have MAP. Up to one-third of patients with disease causing",
"    <em>",
"     APC",
"    </em>",
"    mutations have no family history of the disease and probably represent new germline",
"    <em>",
"     APC",
"    </em>",
"    mutations.",
"   </p>",
"   <p>",
"    The spectrum of diseases caused by mutations in the",
"    <em>",
"     APC",
"    </em>",
"    gene includes classic FAP (more than 100 adenomatous colorectal polyps), the attenuated forms of the disease described below, and an",
"    <em>",
"     APC",
"    </em>",
"    mutation occurring in approximately 6 percent of the Ashkenazi Jewish population that is associated with a modestly increased risk of colon cancer (less than twofold) without polyposis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17016?source=see_link\">",
"     \"Clinical manifestations and diagnosis of familial adenomatous polyposis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to colon adenocarcinoma, patients with FAP are at risk for several extracolonic malignancies, including:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Duodenal ampullary carcinoma",
"     </li>",
"     <li>",
"      Follicular or papillary thyroid cancer",
"     </li>",
"     <li>",
"      Childhood hepatoblastoma",
"     </li>",
"     <li>",
"      Gastric carcinoma",
"     </li>",
"     <li>",
"      Central nervous system (CNS) tumors (mostly medulloblastomas)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Polyps occur commonly in the upper gastrointestinal tract of patients with FAP (30 to 100 percent in various series) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Fundic gland polyps of the proximal stomach are thought to have a very low risk of progression to cancer. Duodenal polyps (present in 45 to 90 percent of patients) are usually adenomatous and can progress to cancer. Patients with FAP have about a 4 to 12 percent lifetime risk of cancer of the duodenum or papilla of Vater. Adenomas in the distal small bowel and in the stomach occur in 20 to 40 percent of patients with FAP but have a much lower cancer risk than duodenal adenomas. Although uncommon, cancer has been reported to occur in the ileostomy following colectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Adenomas occur less commonly in the gallbladder and the bile duct, and adenocarcinomas can occasionally develop at these sites.",
"   </p>",
"   <p>",
"    Gardner's syndrome has traditionally been distinguished clinically from FAP by the presence of prominent extraintestinal lesions. These include desmoid tumors, sebaceous or epidermoid cysts, lipomas, osteomas (especially of the mandible), supernumerary teeth, gastric polyps, and juvenile nasopharyngeal angiofibromas. Gardner's syndrome and FAP can be caused by the same mutation in the",
"    <em>",
"     APC",
"    </em>",
"    gene. Furthermore, if one looks carefully, many patients with FAP have extraintestinal lesions. Turcot's syndrome is a rare variant of FAP that is associated with medulloblastomas. Thus, Gardner's syndrome is a clinical variant of FAP and the distinction between the two is largely semantic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7352?source=see_link\">",
"     \"Gardner syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Genetic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been no prospective controlled trials of gene testing, screening recommendations, or intensity of surveillance in FAP. The recommendations for genetic testing have been largely based on observational studies and consensus expert opinion. The American Gastroenterological Association (AGA) guideline (",
"    <a class=\"graphic graphic_algorithm graphicRef65992 \" href=\"UTD.htm?29/18/29984\">",
"     algorithm 1",
"    </a>",
"    ) for hereditary colorectal cancer and genetic testing [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/8\">",
"     8",
"    </a>",
"    ], as well as other AGA guidelines, can be accessed through the AGA web site at",
"    <a class=\"external\" href=\"file://www.gastro.org/practice/medical-position-statements\">",
"     www.gastro.org/practice/medical-position-statements",
"    </a>",
"    . The following recommendations are consistent with the official guidelines, while providing additional details for addressing practical clinical issues.",
"   </p>",
"   <p>",
"    Genetic testing for FAP is now available from several commercial laboratories. Genetic counseling should be offered prior to any genetic testing [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/9\">",
"     9",
"    </a>",
"    ]. If gene testing is to be performed, it should first be performed on an affected family member. If a mutation is found, the gene test can be used to determine if the other at-risk family members have inherited the mutation. If no mutation is found in the affected family member, other conditions such MUTYH associated polyposis should be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/10\">",
"     10",
"    </a>",
"    ]. If no other cause is found, the gene tests should be considered as uninformative; in this setting, all at-risk family members should undergo endoscopic screening, since commercial tests for",
"    <em>",
"     APC",
"    </em>",
"    and",
"    <em>",
"     MUTYH",
"    </em>",
"    gene mutations do not detect all mutations that can cause FAP [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17016?source=see_link\">",
"     \"Clinical manifestations and diagnosis of familial adenomatous polyposis\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H18\">",
"     'MUTYH associated polyposis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    At-risk family members of patients with classic FAP, Gardner's syndrome, or Turcot's syndrome due to an identified",
"    <em>",
"     APC",
"    </em>",
"    mutation should be offered genetic counseling and testing. At-risk children should usually be offered genetic testing around age 10 to 12. Genetic testing is not recommended in children prior to age 10 because it would not lead to a change in clinical care. A pilot study evaluated the acceptability of prenatal genetic testing in patients with FAP reported that most couples were willing to consider genetic testing. They were especially interested in discussing preimplantation genetic diagnosis to avoid pregnancy termination to prevent transmission of FAP [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/56/23431?source=see_link\">",
"     \"Preimplantation genetic diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H520467283\">",
"    <span class=\"h2\">",
"     Colonic surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gene carriers or at-risk family members who have not had genetic testing or in whom genetic testing is uninformative should be offered a flexible sigmoidoscopy or colonoscopy every 12 months starting around age 10 to 12 and continuing until age 35 to 40 if negative. Classic FAP almost always involves the rectosigmoid so sigmoidoscopy alone is adequate, but many pediatric gastroenterologists are currently screening with colonoscopy. For individuals with attenuated FAP, there is a predominance of right-sided tumors; therefore, full colonoscopy is recommended (see",
"    <a class=\"local\" href=\"#H17\">",
"     'Attenuated FAP'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H520467604\">",
"    <span class=\"h2\">",
"     Surveillance for upper intestinal tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening of the upper gastrointestinal tract with upper endoscopy for gastric and duodenal polyps has been recommended, although the benefit has not been proven in clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/1,13,14\">",
"     1,13,14",
"    </a>",
"    ]. The development of symptoms referable to the upper digestive tract, including pancreatitis or signs or symptoms related to biliary obstruction, should prompt an investigation of the stomach and duodenum, with particular attention to the papilla of Vater. In the absence of symptoms, upper endoscopic screening should be initiated around age 25 to 30 years, or earlier if there is a history of early age gastroduodenal cancer in the family. Screening intervals vary depending on the type of gastroduodenal polyps identified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H342946992\">",
"    <span class=\"h3\">",
"     Spigelman classification of duodenal polyposis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been attempts to identify patients at greatest risk for the development of adenocarcinoma of the duodenum. The most commonly used classification system (the Spigelman classification) recognizes five grade scales (stages 0 to IV) based upon the number of polyps (1 to 4, 4 to 20, &gt;20), their size in mm (1 to 4, 5 to 10, and &gt;10), histology (tubular, tubulovillous, villous), and severity of dysplasia (mild, moderate, severe) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/15\">",
"     15",
"    </a>",
"    ]. A modification of this classification system includes points for the degree of dysplasia (",
"    <a class=\"graphic graphic_table graphicRef71691 \" href=\"UTD.htm?30/39/31355\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/16\">",
"     16",
"    </a>",
"    ]. Patients with stage IV disease appear to be at the greatest risk for developing duodenal adenocarcinoma.",
"   </p>",
"   <p>",
"    The absolute rate of progression of duodenal polyposis remains uncertain since several studies addressing this issue have provided variable results [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/16-20\">",
"     16-20",
"    </a>",
"    ]. One of the largest studies included 180 patients with FAP who had been screened by upper endoscopy and were enrolled in a Swedish registry [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/17\">",
"     17",
"    </a>",
"    ]. A Spigelman stage IV adenoma was diagnosed in 14 patients with a cumulative risk of a stage IV adenoma of 20 percent by age 60 years. Periampullary adenocarcinoma was diagnosed in five patients (2.8 percent) with a cumulative risk of 10 percent by age 60 years. Three of these cancers occurred in patients with stage IV disease (odds ratio 31, 95% CI 4.6 to 215). The author of an accompanying editorial recommended that serious consideration be given to prophylactic duodenectomy for patients with stage IV disease since the majority of patients with periampullary carcinoma arising in this setting developed disease progression despite endoscopic surveillance [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A potentially more aggressive rate of progression was suggested in a study that included 58 patients with FAP who underwent surveillance endoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/16\">",
"     16",
"    </a>",
"    ]. During a median of 48 months, 35 patients underwent at least two consecutive examinations and were the basis for analysis. The modified Spigelman's score increased in 21 patients (60 percent), and 12 patients (34 percent) developed high-grade dysplasia. A high initial modified Spigelman's score (&gt;7 points), but not age or",
"    <em>",
"     APC",
"    </em>",
"    mutation site, correlated with development of high-grade dysplasia (results that differed from an earlier report from another group [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/22\">",
"     22",
"    </a>",
"    ]). The authors estimated that the cumulative risk of developing stage IV polyposis was 43 percent at age 60 and 50 percent at age 70.",
"   </p>",
"   <p>",
"    The Spigelman classification does appear to stratify risk in patients with duodenal polyposis but does not appear to be an accurate predictor of cancers developing in the ampulla [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/23\">",
"     23",
"    </a>",
"    ]. Thus, it is recommended that ampullary adenomas be classified separately as major if they are &gt;1 cm in size, have high-grade dysplasia or villous architecture, or minor of they have none of these features [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/23\">",
"     23",
"    </a>",
"    ]. Patients with major ampullary adenomas should have endoscopic or surgical resection of the ampulla or annual upper endoscopic surveillance to evaluate for progression that would warrant resection. Three-year surveillance intervals have been recommended for patients with minor ampullary adenomas.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H342946999\">",
"    <span class=\"h3\">",
"     Fundic gland polyps",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fundic gland polyps are common in FAP and have a very different clinical significance than gastroduodenal adenomas. Fundic gland polyps are typically located in the proximal stomach (hence their name), tend to be small (&lt;1 cm), and can be profuse. Histologically, fundic gland polyps are characterized by a mix of cystically dilated oxyntic glands with distorted glandular architecture and normal appearing glands and they have generally not been considered to have a significant malignant potential. However, dysplasia does occur in fundic gland polyps and isolated reports of malignant degeneration exist.",
"   </p>",
"   <p>",
"    One series of 75 consecutive patients undergoing upper endoscopy for FAP described features associated with dysplasia in fundic gland polyps [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/24\">",
"     24",
"    </a>",
"    ]. Fundic gland polyps were detected in 88 percent of patients and, of those biopsied, 41 percent had dysplasia (38 percent low-grade and 2 percent high-grade). Helicobacter pylori infection was rare in patients with fundic gland polyps compared with those without fundic gland polyps (1.5 versus 33 percent). On multivariable analysis, larger polyp size, higher stage of associated duodenal polyposis, and antral gastritis were associated with dysplasia. Interestingly, use of acid suppressive medications was associated with a decrease in the risk of dysplasia (odds ratio 0.14, 95% CI 0.03-0.64). Sampling of fundic gland polyps is recommended in patients with FAP to confirm their histology along with biopsy or complete polypectomy of large or irregular appearing polyps to assess for dysplasia.",
"   </p>",
"   <p>",
"    In contrast to fundic gland polyps, antral polyps are usually adenomas and should be completely removed endoscopically if possible.",
"   </p>",
"   <p>",
"    The upper endoscopic surveillance intervals are generally dictated by the severity of duodenal polyposis and the presence of non-dysplastic fundic gland polyps should generally not alter the recommended screening intervals [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Some authors suggest that the presence of dysplasia within fundic gland polyps should prompt more frequent upper endoscopic surveillance [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H342947006\">",
"    <span class=\"h3\">",
"     Recommendations from expert groups",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h4\">",
"     American Society for Gastrointestinal Endoscopy recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2006, the American Society for Gastrointestinal Endoscopy (ASGE) issued recommendations for screening and surveillance of the upper digestive tract [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/27\">",
"     27",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with FAP should undergo upper endoscopy with both end-viewing and side-viewing instruments. The optimal timing of initial upper endoscopy is unknown, but could be performed around the time the patient is considered for colectomy, or early in the third decade of life. If no adenomas are detected, another exam should be performed in five years because adenomatous change may occur later in the course of the disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39185233\">",
"    <span class=\"h4\">",
"     European guidelines",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2008, a panel of experts from Europe issued screening and surveillance guidelines for patients with FAP [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/28\">",
"     28",
"    </a>",
"    ]. With regard to duodenal surveillance, the guidelines recommend that:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Screening for duodenal adenomas should commence between the ages of 25 and 30 years.",
"     </li>",
"     <li>",
"      The surveillance interval depends upon the patient&rsquo;s Spigelman classification (",
"      <a class=\"graphic graphic_table graphicRef71691 \" href=\"UTD.htm?30/39/31355\">",
"       table 1",
"      </a>",
"      ) (see",
"      <a class=\"local\" href=\"#H342946992\">",
"       'Spigelman classification of duodenal polyposis'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Stage 0 or 1: Five years",
"     </li>",
"     <li>",
"      Stage II: Three years",
"     </li>",
"     <li>",
"      Stage III: One to two years",
"     </li>",
"     <li>",
"      Stage IV: Consider surgery",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55554528\">",
"    <span class=\"h4\">",
"     Other groups",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other expert groups [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/29,30\">",
"     29,30",
"    </a>",
"    ] have suggested slightly different approaches or additional surveillance approaches for specific findings in the upper digestive tract, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A baseline examination with both an end- and side-viewing endoscope and repeat examinations every three to five years as long as no polyps are found.",
"     </li>",
"     <li>",
"      Complete polypectomy or sampling of duodenal polyps at the time of initial discovery and on each subsequent examination to determine the stage of duodenal polyposis. The frequency of examinations and referral for prophylactic surgery are determined on the basis of duodenal polyp stage.",
"     </li>",
"     <li>",
"      Adenomas identified in the duodenum or the papilla of Vater should be removed endoscopically if possible, and follow-up examination should be performed yearly [",
"      <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/30\">",
"       30",
"      </a>",
"      ]. Any abnormal appearing papilla should be biopsied, since adenomas in the duodenum have a predilection for the papilla. Some authorities also recommend obtaining routine biopsies of the papilla, even if it appears grossly normal. A side-viewing endoscope is better suited for this purpose. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26950?source=see_link\">",
"       \"Clinical manifestations and diagnosis of ampullary adenomas\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13897?source=see_link\">",
"       \"Treatment of ampullary adenomas\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with periampullary adenomas, endoscopic treatment may be appropriate in selected patients. If excision is complete, surveillance endoscopy and multiple biopsies is performed every six months for a minimum of two years, with endoscopy thereafter at three-year intervals.",
"     </li>",
"     <li>",
"      Surgical consultation for patients with advanced (Spigelman stage IV) duodenal polyposis (see",
"      <a class=\"local\" href=\"#H342946992\">",
"       'Spigelman classification of duodenal polyposis'",
"      </a>",
"      above) in an effort to prevent",
"      <span class=\"nowrap\">",
"       periampullary/duodenal",
"      </span>",
"      carcinoma. Management of high-grade dysplasia in the periampullary region",
"      <span class=\"nowrap\">",
"       (surgery/ablative",
"      </span>",
"      therapy versus more frequent surveillance) is controversial and should be individualized. (See",
"      <a class=\"local\" href=\"#H342946992\">",
"       'Spigelman classification of duodenal polyposis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Screening for extraintestinal malignancies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening recommendations for extraintestinal lesion in FAP have also been suggested:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Careful palpation of the thyroid is recommended annually for all patients with FAP, including asymptomatic gene carriers. Fine-needle aspiration may be required to exclude cancer in patients with nodules [",
"      <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Some experts recommend that children at risk for FAP, particularly in families that have a history of hepatoblastoma, should undergo testing for serum alpha-fetoprotein and have abdominal palpation every six months until the age of six [",
"      <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/32\">",
"       32",
"      </a>",
"      ]. Serum alpha-fetoprotein is elevated in approximately two-thirds of patients with a hepatoblastoma.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21725627\">",
"    <span class=\"h2\">",
"     Surveillance for benign extraintestinal manifestations",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21725661\">",
"    <span class=\"h3\">",
"     Adrenal tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lifetime prevalence of adrenal tumors is 7 to 13 percent in individuals with FAP. The tumors typically present after the age of 14 years [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/33\">",
"     33",
"    </a>",
"    ]. The tumors are rarely malignant and routine surveillance is not recommended. However, it is important to be aware of the symptoms related to an excess of the cortisol, aldosterone, androgens, or catecholamines (eg, hypertension, hirsutism, or weight gain), which may prompt a hormonal analysis and referral to endocrinology. Adrenal masses are often detected incidentally with imaging studies conducted for other reasons. Surgery is generally indicated for masses larger than 6 cm because they often have a malignant component. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12826?source=see_link\">",
"     \"Clinical presentation and evaluation of adrenocortical tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18569?source=see_link\">",
"     \"The adrenal incidentaloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21725668\">",
"    <span class=\"h3\">",
"     Desmoid tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The lifetime prevalence of desmoid tumors is about 20 percent with a peak incidence around 30 years, but they can be seen at any age [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/33\">",
"     33",
"    </a>",
"    ]. The risk of desmoids is increased in individuals with a family history of desmoids, a personal history of osteomas, and following abdominal surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. It is unclear if women and individuals with an",
"    <em>",
"     APC",
"    </em>",
"    mutation 3&rsquo; of codon 1444 are at increased risk for developing FAP-related desmoids [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/34-41\">",
"     34-41",
"    </a>",
"    ]. Desmoid tumors arise most frequently intra-abdominally, but also in the abdominal wall. Fewer than 10 percent are located outside the abdomen. There is no surveillance recommended for desmoids, but as individuals with FAP are living longer due to increased surveillance and improved surgical results for treatment of the polyposis, desmoids are becoming an increasing source of morbidity and mortality in FAP. Some centers consider obtaining a CT or MRI scan for evaluation of desmoids. The presence of intra-abdominal desmoids may play a role in the type of surgery recommended and, depending on the number of polyps present, may play a role in when surgery is performed.",
"   </p>",
"   <p>",
"    Patients with palpable abdominal masses or symptoms suggestive of abdominal organ obstruction require evaluation. Treatment is indicated when desmoids cause symptoms, pose a great risk to adjacent structures, or create cosmetic concerns. For intra-abdominally located tumors, treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/17/44312?source=see_link\">",
"     sulindac",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    is the advised first-line therapy. Cytotoxic chemotherapy has been used for desmoids that are not responsive to less aggressive therapies. Surgery is generally not recommended as first-line therapy for intra-abdominal desmoids because recurrence rates and morbidity are high. It is commonly believed that resection triggers growth and therefore recurrences. Surgery is indicated as first-line therapy for tumors located in the abdominal wall and extra-abdominally. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30906?source=see_link\">",
"     \"Desmoid tumors: Epidemiology, risk factors, molecular pathogenesis, clinical presentation, diagnosis, and local therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/38/11881?source=see_link\">",
"     \"Desmoid tumors: Systemic therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21725675\">",
"    <span class=\"h3\">",
"     Osteomas and dental abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteomas are benign growths of bone that occur most commonly in the skull and mandible. The lifetime risk for osteomas is about 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/33\">",
"     33",
"    </a>",
"    ]. They are seen more frequently in individuals who have a family history of osteomas. No specific surveillance is recommended. Referral to a dental surgeon is recommended if osteomas, dentigerous cysts, or supernumerary teeth cause problems.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once colonic polyposis is established in a gene carrier or an at-risk member of an FAP family, a full colonoscopy should be performed to evaluate the extent of the colonic polyposis. An initial upper endoscopic exam should also be performed (see",
"    <a class=\"local\" href=\"#H19\">",
"     'Screening'",
"    </a>",
"    below) and a consultation should be arranged to discuss the timing of a colectomy. The number, size, and worst histology of the colonic adenomas determine the optimal timing of colectomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H194153889\">",
"    <span class=\"h3\">",
"     Colectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colectomy near the time of initial diagnosis is strongly recommended in patients with multiple large (&gt;1 cm) adenomas or adenomas with villous histology",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    high-grade dysplasia and is the safest approach for patients with profuse polyposis at initial diagnosis. Patients in the second decade of life with only sparse, small (&lt;5 mm) adenomas can usually be followed endoscopically with surgery scheduled to accommodate school and work schedules.",
"   </p>",
"   <p>",
"    Some centers try to allow such patients to finish high school if the endoscopic appearance of the colon is stable, to minimize the psychological trauma of a colectomy during adolescence. The preferred operation in children with profuse polyposis included the rectum is a total proctocolectomy with ileoanal anastomosis. A subtotal colectomy with ongoing surveillance or a total colectomy is reasonable in patients with attenuated adenomatous polyposis who have minor rectal involvement (fewer than 20 or so adenomas in the rectum). One study suggested that the specific",
"    <em>",
"     APC",
"    </em>",
"    genotype may be useful in predicting which patients would be better suited for ileorectal anastomosis versus total proctocolectomy with ileal-pouch-anal anastomosis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who have undergone total proctocolectomy remain at risk for the development of adenomas and adenocarcinoma in the ileal pouch [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/6,7,43\">",
"     6,7,43",
"    </a>",
"    ], although the precise magnitude of the risk is not clear. In one series of 167 patients who were followed for up to 15 years following colectomy, the risk of developing one or more adenomas in the ileal pouch was 7, 35, and 75 percent at 5, 10, and 15 years follow-up, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By contrast, another report of 212 patients found that despite the high risk of adenomas, the risk of malignant degeneration appeared to be low [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/44\">",
"     44",
"    </a>",
"    ]. The cumulative risk of developing an adenoma in the pouch at 10-year follow-up was 45 percent, while 25 patients (12 percent) developed an adenoma with advanced pathology and four patients (2 percent) developed a cancer. The cumulative risk of developing a pouch cancer was estimated to be 1 percent at 10 years. The authors of the above report [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/44\">",
"     44",
"    </a>",
"    ] recommended yearly surveillance, since the median interval between a prior endoscopy and the detection of cancer was 25 months. Regardless of the precise risk estimates, regular surveillance of any remaining rectum or the ileal pouch is recommended after colectomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12142671\">",
"    <span class=\"h3\">",
"     Chemoprevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of colon adenocarcinoma in classic FAP approaches 100 percent by age 45 years. Colonoscopy alone is",
"    <strong>",
"     not",
"    </strong>",
"    effective for identifying polyps with advanced pathology or in detecting early cancers because the presence of multiple polyps precludes adequate sampling. Thus, there has been an active interest in chemoprevention of colonic and duodenal adenomas in FAP.",
"   </p>",
"   <p>",
"    Although the nonsteroidal antiinflammatory drug (NSAID)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/17/44312?source=see_link\">",
"     sulindac",
"    </a>",
"    can cause regression of colorectal adenomas in FAP, regression of polyps is incomplete and the degree of protection from the development of colorectal cancer is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. There have been reports of individuals with complete disappearance of polyps on sulindac but subsequent development of cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/47\">",
"     47",
"    </a>",
"    ]. In one controlled trial involving 41 proven FAP gene carriers, sulindac (75 or 150 mg twice daily) was ineffective in delaying the time of initial development of adenomas in a controlled trial involving 41 proven FAP gene carriers [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"     Celecoxib",
"    </a>",
"    has also been shown to modestly reduce the number of colonic polyps (28 percent reduction) in adults with FAP [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/49\">",
"     49",
"    </a>",
"    ]. In another trial of 18 children with FAP, celecoxib (16 mg per kg daily) significantly reduced the number of colorectal polyps (44 percent) compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/50\">",
"     50",
"    </a>",
"    ]. Celecoxib has been approved by the FDA as an adjunct to surgical therapy for patients with FAP. Although NSAIDs are not recommended to replace colectomy as primary therapy for FAP, they are being used in some centers to slow the development of adenomas prior to colectomy and to delay new polyp formation in the rectum after subtotal colectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A possible role of preventing the progression of duodenal adenomas with COX-2 inhibitors was supported by a controlled trial in which a total of 83 patients with FAP were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/11/40120?source=see_link\">",
"     celecoxib",
"    </a>",
"    (100 or 400 mg twice daily) or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/52\">",
"     52",
"    </a>",
"    ]. After six months, patients receiving the higher dose had a modest (15 percent) but statistically significant reduction in the extent of duodenal polyposis as assessed in blinded reviews of endoscopy videotapes. Some centers recommend celecoxib for treatment of advanced Spigelman stage duodenal polyposis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Attenuated FAP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinically attenuated FAP (AFAP) differs from classic FAP by having fewer colonic adenomas (10 to 100), a lower but still high (up to 80 percent) lifetime risk of colon cancer, and a later age of diagnosis of both colonic polyps (average 40 to 45 years of age) and colon cancer (average about 50 to 60 years of age) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/53-55\">",
"     53-55",
"    </a>",
"    ]. In fact, some patients with AFAP have no adenomas. Disease severity tends to be similar in members of the same family [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Consideration of genetic testing for AFAP is recommended in patients with more than 10 to 20 cumulative colonic adenomas. However, no detectable",
"    <em>",
"     APC",
"    </em>",
"    mutation will be found in up to 90 percent of patients at the low end of this range [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/2\">",
"     2",
"    </a>",
"    ]. The",
"    <em>",
"     APC",
"    </em>",
"    mutations in AFAP have mainly been detected in three parts of the gene: in the 5' end (the first five exons), in exon 9, and in the distal 3' end [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    AFAP is also usually characterized by a more proximal distribution of adenomas with more frequent involvement of the proximal colon than of the rectum. The cumulative colon cancer risk by the age of 80 years is estimated to be 60 to 70 percent, with about 75 percent of tumors occurring in the proximal colon [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/54,55,57\">",
"     54,55,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Colonoscopic and endoscopic screening has been recommended in patients with AFAP starting at the age of 20 to 25 years. Patients with colonoscopic findings consistent with AFAP may undergo polypectomy when feasible, followed by continued yearly surveillance. Patients with adenomas too numerous to clear endoscopically, or for whom endoscopic surveillance is not technically possible, should be considered for prophylactic colectomy.",
"   </p>",
"   <p>",
"    Patients with AFAP can also develop duodenal adenomas and periampullary carcinomas, as in classic FAP. Upper endoscopy is recommended starting at age 20 to 30 years and then every one to three years, depending on polyp burden. Extraintestinal tumors, particularly desmoids [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/56\">",
"     56",
"    </a>",
"    ], can occur in AFAP. There is no consensus on screening for extraintestinal tumors in AFAP, and a conservative approach would be to manage these individuals as if they had classic FAP until more data are available. (See",
"    <a class=\"local\" href=\"#H520467604\">",
"     'Surveillance for upper intestinal tumors'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     MUTYH ASSOCIATED POLYPOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;MUTYH associated polyposis (MAP) is an autosomal recessive polyposis syndrome caused by biallelic mutations in the",
"    <em>",
"     MUTYH",
"    </em>",
"    gene [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/10\">",
"     10",
"    </a>",
"    ]. MAP is currently the only known recessive hereditary colon cancer syndrome. The two most common",
"    <em>",
"     MUTYH",
"    </em>",
"    gene mutations found in MAP in the Caucasian population are Y179C and G396D, but about 20 percent of cases with biallelic mutations do not have either of these mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical spectrum of MAP is variable. The early descriptions of MAP were in patients with a clinical phenotype similar to attenuated FAP (AFAP) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/58\">",
"     58",
"    </a>",
"    ] or with a clinical picture overlapping that of classic FAP (100 to up to 500 adenomas) [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. Subsequently, other patients with biallelic",
"    <em>",
"     MUTYH",
"    </em>",
"    gene mutations were reported to present with early onset (age &lt;50 years) cancer without polyposis [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/58-60\">",
"     58-60",
"    </a>",
"    ]. A large-scale meta-analysis showed a 28-fold (95% CI 6.95-115) increase in colon cancer risk in biallelic mutation carriers [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is a higher incidence of colon cancer at the time of polyposis diagnosis in patients with MAP compared with AFAP [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/62-64\">",
"     62-64",
"    </a>",
"    ]. Approximately two-thirds of these cancers are right-sided and the mean age at diagnosis is approximately 45 years.",
"   </p>",
"   <p>",
"    Extracolonic features have also been described, including gastroduodenal polyps, duodenal carcinoma, osteomas, breast cancer in female carriers, congenital hypertrophy of the retinal pigment epithelium (CHERPE), dental cysts, and Muir Torre phenotype with sebaceous gland tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/64\">",
"     64",
"    </a>",
"    ], but are less common than in FAP. The extraintestinal cancer risk is substantial in MAP and the distribution of cancers seen varies from that seen with FAP. There appears to be an increased risk of ovarian, bladder, skin, and possibly breast cancer in MAP [",
"    <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/60,65\">",
"     60,65",
"    </a>",
"    ]",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three screening issues related to MAP: screening to establish the diagnosis, screening for possible malignancy in known carriers, and screening for possible malignancy in monoallelic carriers.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Screening to establish the diagnosis has been suggested in patients with multiple colorectal adenomas (&gt;10 to 20) who are adenomatous polyposis coli (",
"      <em>",
"       APC",
"      </em>",
"      )-negative (ie, do not have familial adenomatous polyposis) or have apparent autosomal recessive inheritance [",
"      <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/10,63\">",
"       10,63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There are currently no widely accepted screening guidelines in patients with documented MAP. Some recommend colonoscopy starting at age 18 for biallelic carriers or those who do not choose to pursue genetic testing [",
"      <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/28,58\">",
"       28,58",
"      </a>",
"      ]. Others recommend both upper and lower endoscopy starting at age 25 to 30 years of age. Surgical therapy should depend upon clinical and endoscopic findings rather than on mutation analysis.",
"     </li>",
"     <li>",
"      Women with biallelic",
"      <em>",
"       MUTYH",
"      </em>",
"      gene mutations may consider high-risk breast cancer screening with two annual clinical breast examinations in addition to annual mammograms and monthly self breast examinations.",
"     </li>",
"     <li>",
"      The risk of colorectal cancer in monoallelic",
"      <em>",
"       MUTYH",
"      </em>",
"      gene carriers has not been clearly defined [",
"      <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/61,66,67\">",
"       61,66,67",
"      </a>",
"      ]. In a meta-analysis there was no significant increase in CRC risk in individuals with monoallelic G396D mutations [",
"      <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/61\">",
"       61",
"      </a>",
"      ]. However, individuals with a monoallelic Y179C mutation had a 1.3-fold increased risk of colorectal cancer (95% CI 1.01-1.77). If monoallelic carriers have even a modestly increased risk for colorectal cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/59\">",
"       59",
"      </a>",
"      ], it is a clinically important issue since monoallelic",
"      <em>",
"       MUTYH",
"      </em>",
"      gene mutations are common in the population (up to 1 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?16/14/16618/abstract/68\">",
"       68",
"      </a>",
"      ] and would be present in both parents and half the siblings of patients with MAP. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/41/9881?source=see_link\">",
"       \"Screening for colorectal cancer: Strategies in patients with possible increased risk due to family history\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/34/25123?source=see_link\">",
"       \"Patient information: Colon and rectal cancer screening (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/11/18611?source=see_link\">",
"       \"Patient information: Colonoscopy (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/47/21234?source=see_link\">",
"       \"Patient information: Familial adenomatous polyposis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?7/23/7541?source=see_link\">",
"       \"Patient information: Colon and rectal cancer screening (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?9/30/9698?source=see_link\">",
"       \"Patient information: Colonoscopy (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?41/12/42176?source=see_link\">",
"       \"Patient information: Flexible sigmoidoscopy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21761522\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial adenomatous polyposis (FAP) is an autosomal dominant disease caused by mutations in the adenomatous polyposis coli (",
"    <em>",
"     APC",
"    </em>",
"    ) gene. Patients with FAP are at high risk for the development of colorectal cancer as well as the development of upper intestinal and extraintestinal tumors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17016?source=see_link\">",
"     \"Clinical manifestations and diagnosis of familial adenomatous polyposis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An attenuated form of FAP (AFAP) is also caused by",
"    <em>",
"     APC",
"    </em>",
"    mutations, but is characterized by fewer polyps, lower colon cancer risk, and later age of colon cancer onset.",
"   </p>",
"   <p>",
"    MUTYH associated polyposis (MAP) is an autosomal recessive polyposis syndrome caused by biallelic mutations in the",
"    <em>",
"     MUTYH",
"    </em>",
"    gene. Affected patients have a clinical phenotype similar to attenuated or classic FAP. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'MUTYH associated polyposis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    We recommend that family members of patients with classic FAP and its variants (Gardner's syndrome, Turcot's syndrome, AFAP) and those with MAP be offered genetic counseling and testing when appropriate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16161335\">",
"    <span class=\"h2\">",
"     Classic FAP",
"    </span>",
"   </p>",
"   <p>",
"    We recommend the following approach in patients with classic familial adenomatous polyposis for the surveillance and prevention of colonic tumors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Genetic screening of at-risk family members of known FAP families or in patients with more than 100 adenomas.",
"     </li>",
"     <li>",
"      Screening of gene carriers or at-risk family members, if genetic testing cannot be done or is uninformative, with a flexible sigmoidoscopy or colonoscopy every 12 months starting around age 10 to 12 years and continuing until age 35 to 40 years if negative.",
"     </li>",
"     <li>",
"      Once colonic polyposis is established, a full colonoscopy should be performed to evaluate the extent of the colonic polyposis.",
"     </li>",
"     <li>",
"      Colectomy near the time of initial diagnosis in patients with profuse polyposis, multiple large (&gt;1 cm) adenomas, or adenomas with villous histology",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      high-grade dysplasia.",
"     </li>",
"     <li>",
"      Patients with sparse, small (&lt;5 mm) adenomas can usually be followed endoscopically with surgery scheduled to accommodate school and work schedules.",
"     </li>",
"     <li>",
"      Patients who have undergone total proctocolectomy require regular surveillance of the ileal pouch.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We suggest the following approach for surveillance and prevention of extracolonic tumors (see",
"    <a class=\"local\" href=\"#H520467604\">",
"     'Surveillance for upper intestinal tumors'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Screening of the upper gastrointestinal tract with upper endoscopy using a forward-viewing endoscope for gastric polyps and a side-viewing endoscope for duodenal polyps at the time of onset of colonic polyps or around age 20 to 25 years (whichever comes first).",
"     </li>",
"     <li>",
"      Endoscopic removal of adenomas identified in the duodenum or the papilla of Vater with follow-up endoscopy based upon the stage of the polyposis:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Stage 0 or I: Five years",
"     </li>",
"     <li>",
"      Stage II: Three years",
"     </li>",
"     <li>",
"      Stage III: One to two years",
"     </li>",
"     <li>",
"      Stage IV: Consider surgery; if surgery is not performed, we perform follow-up endoscopies every six months",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Performance of routine biopsies of the papilla if any abnormality is noted or if there is a history of pancreatitis or biliary obstruction.",
"     </li>",
"     <li>",
"      Management of high-grade dysplasia in the periampullary region",
"      <span class=\"nowrap\">",
"       (surgery/ablative",
"      </span>",
"      therapy versus more frequent surveillance) is controversial and must be individualized.",
"     </li>",
"     <li>",
"      Proximal gastric polyps should be biopsied to confirm that they are fundic gland polyps and to assess for dysplasia. Antral polyps are usually adenomas and should be removed endoscopically if possible.",
"     </li>",
"     <li>",
"      Careful palpation of the thyroid annually. Fine-needle aspiration may be required to exclude cancer in patients with nodules.",
"     </li>",
"     <li>",
"      Children with FAP and a family history of hepatoblastoma should undergo testing for serum alpha-fetoprotein and have abdominal palpation every six months until the age of six.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16161342\">",
"    <span class=\"h2\">",
"     Attenuated FAP",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest the following approach in patients with attenuated familial adenomatous polyposis (AFAP) (see",
"    <a class=\"local\" href=\"#H17\">",
"     'Attenuated FAP'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Genetic testing of at-risk family members of known AFAP families or in patients with more than 10 to 20 colonic adenomas.",
"     </li>",
"     <li>",
"      Colonoscopy screening annually in gene carriers and in at-risk family members if genetic testing cannot be performed or is uninformative starting at the age of 20 to 25 years.",
"     </li>",
"     <li>",
"      Patients with AFAP may be managed with polypectomy followed by yearly surveillance, provided that the polyps can be removed.",
"     </li>",
"     <li>",
"      Prophylactic colectomy is recommended for patients with adenomas too numerous to clear endoscopically, or for whom endoscopic surveillance is not technically possible.",
"     </li>",
"     <li>",
"      There is no consensus on screening for extracolonic tumors in AFAP. We suggest managing these individuals as if they had classic FAP until more data are available.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16161349\">",
"    <span class=\"h2\">",
"     MUTYH associated polyposis",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are currently no widely accepted screening guidelines in patients with documented MUTYH associated polyposis (MAP). We suggest the following approach in patients with MAP (see",
"    <a class=\"local\" href=\"#H19\">",
"     'Screening'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Genetic testing in patients with more than 10 to 20 adenomas who are negative for",
"      <em>",
"       APC",
"      </em>",
"      mutations or have an apparent autosomal recessive inheritance pattern.",
"     </li>",
"     <li>",
"      Colonoscopy every one to two years starting around age 25 to 30 years for biallelic",
"      <em>",
"       MUTYH",
"      </em>",
"      gene mutation carriers.",
"     </li>",
"     <li>",
"      Colectomy should be considered in patients who cannot be managed with endoscopic polypectomy.",
"     </li>",
"     <li>",
"      Upper endoscopic screening every two to five years starting at age 25 to 30 years.",
"     </li>",
"     <li>",
"      Advising patients of the increased risk of bladder, skin, ovarian, and breast cancer and discussing screening for these extraintestinal cancers.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/1\">",
"      Lindor NM, Greene MH. The concise handbook of family cancer syndromes. Mayo Familial Cancer Program. J Natl Cancer Inst 1998; 90:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/2\">",
"      Russell AM, Zhang J, Luz J, et al. Prevalence of MYH germline mutations in Swiss APC mutation-negative polyposis patients. Int J Cancer 2006; 118:1937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/3\">",
"      Laken SJ, Petersen GM, Gruber SB, et al. Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. Nat Genet 1997; 17:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/4\">",
"      Jagelman DG, DeCosse JJ, Bussey HJ. Upper gastrointestinal cancer in familial adenomatous polyposis. Lancet 1988; 1:1149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/5\">",
"      Wallace MH, Phillips RK. Upper gastrointestinal disease in patients with familial adenomatous polyposis. Br J Surg 1998; 85:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/6\">",
"      Hamilton SR, Bussey HJ, Mendelsohn G, et al. Ileal adenomas after colectomy in nine patients with adenomatous polyposis coli/Gardner's syndrome. Gastroenterology 1979; 77:1252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/7\">",
"      Primrose JN, Quirke P, Johnston D. Carcinoma of the ileostomy in a patient with familial adenomatous polyposis. Br J Surg 1988; 75:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/8\">",
"      American Gastroenterological Association. American Gastroenterological Association medical position statement: hereditary colorectal cancer and genetic testing. Gastroenterology 2001; 121:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/9\">",
"      Robson ME, Storm CD, Weitzel J, et al. American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. J Clin Oncol 2010; 28:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/10\">",
"      Sieber OM, Lipton L, Crabtree M, et al. Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. N Engl J Med 2003; 348:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/11\">",
"      Laken SJ, Papadopoulos N, Petersen GM, et al. Analysis of masked mutations in familial adenomatous polyposis. Proc Natl Acad Sci U S A 1999; 96:2322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/12\">",
"      Kastrinos F, Stoffel EM, Balma&ntilde;a J, Syngal S. Attitudes toward prenatal genetic testing in patients with familial adenomatous polyposis. Am J Gastroenterol 2007; 102:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/13\">",
"      Heiskanen I, Kellokumpu I, J&auml;rvinen H. Management of duodenal adenomas in 98 patients with familial adenomatous polyposis. Endoscopy 1999; 31:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/14\">",
"      Attard TM, Cuffari C, Tajouri T, et al. Multicenter experience with upper gastrointestinal polyps in pediatric patients with familial adenomatous polyposis. Am J Gastroenterol 2004; 99:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/15\">",
"      Spigelman AD, Williams CB, Talbot IC, et al. Upper gastrointestinal cancer in patients with familial adenomatous polyposis. Lancet 1989; 2:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/16\">",
"      Saurin JC, Gutknecht C, Napoleon B, et al. Surveillance of duodenal adenomas in familial adenomatous polyposis reveals high cumulative risk of advanced disease. J Clin Oncol 2004; 22:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/17\">",
"      Bj&ouml;rk J, Akerbrant H, Iselius L, et al. Periampullary adenomas and adenocarcinomas in familial adenomatous polyposis: cumulative risks and APC gene mutations. Gastroenterology 2001; 121:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/18\">",
"      Nugent KP, Spigelman AD, Williams CB, et al. Surveillance of duodenal polyps in familial adenomatous polyposis: progress report. J R Soc Med 1994; 87:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/19\">",
"      Burke CA, Beck GJ, Church JM, van Stolk RU. The natural history of untreated duodenal and ampullary adenomas in patients with familial adenomatous polyposis followed in an endoscopic surveillance program. Gastrointest Endosc 1999; 49:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/20\">",
"      Groves CJ, Saunders BP, Spigelman AD, Phillips RK. Duodenal cancer in patients with familial adenomatous polyposis (FAP): results of a 10 year prospective study. Gut 2002; 50:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/21\">",
"      Burke C. Risk stratification for periampullary carcinoma in patients with familial adenomatous polyposis: does theodore know what to do now? Gastroenterology 2001; 121:1246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/22\">",
"      Saurin JC, Ligneau B, Ponchon T, et al. The influence of mutation site and age on the severity of duodenal polyposis in patients with familial adenomatous polyposis. Gastrointest Endosc 2002; 55:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/23\">",
"      Latchford AR, Neale KF, Spigelman AD, et al. Features of duodenal cancer in patients with familial adenomatous polyposis. Clin Gastroenterol Hepatol 2009; 7:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/24\">",
"      Bianchi LK, Burke CA, Bennett AE, et al. Fundic gland polyp dysplasia is common in familial adenomatous polyposis. Clin Gastroenterol Hepatol 2008; 6:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/25\">",
"      Park JG, Park KJ, Ahn YO, et al. Risk of gastric cancer among Korean familial adenomatous polyposis patients. Report of three cases. Dis Colon Rectum 1992; 35:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/26\">",
"      Offerhaus GJ, Giardiello FM, Krush AJ, et al. The risk of upper gastrointestinal cancer in familial adenomatous polyposis. Gastroenterology 1992; 102:1980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/27\">",
"      Hirota WK, Zuckerman MJ, Adler DG, et al. ASGE guideline: the role of endoscopy in the surveillance of premalignant conditions of the upper GI tract. Gastrointest Endosc 2006; 63:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/28\">",
"      Vasen HF, M&ouml;slein G, Alonso A, et al. Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut 2008; 57:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/29\">",
"      Brosens LA, Keller JJ, Offerhaus GJ, et al. Prevention and management of duodenal polyps in familial adenomatous polyposis. Gut 2005; 54:1034.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/30\">",
"      Norton ID, Geller A, Petersen BT, et al. Endoscopic surveillance and ablative therapy for periampullary adenomas. Am J Gastroenterol 2001; 96:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/31\">",
"      Herraiz M, Barbesino G, Faquin W, et al. Prevalence of thyroid cancer in familial adenomatous polyposis syndrome and the role of screening ultrasound examinations. Clin Gastroenterol Hepatol 2007; 5:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/32\">",
"      Hughes LJ, Michels VV. Risk of hepatoblastoma in familial adenomatous polyposis. Am J Med Genet 1992; 43:1023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/33\">",
"      Groen EJ, Roos A, Muntinghe FL, et al. Extra-intestinal manifestations of familial adenomatous polyposis. Ann Surg Oncol 2008; 15:2439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/34\">",
"      Bertario L, Russo A, Sala P, et al. Genotype and phenotype factors as determinants of desmoid tumors in patients with familial adenomatous polyposis. Int J Cancer 2001; 95:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/35\">",
"      Nieuwenhuis MH, Lefevre JH, B&uuml;low S, et al. Family history, surgery, and APC mutation are risk factors for desmoid tumors in familial adenomatous polyposis: an international cohort study. Dis Colon Rectum 2011; 54:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/36\">",
"      Nieuwenhuis MH, Casparie M, Mathus-Vliegen LM, et al. A nation-wide study comparing sporadic and familial adenomatous polyposis-related desmoid-type fibromatoses. Int J Cancer 2011; 129:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/37\">",
"      Sturt NJ, Gallagher MC, Bassett P, et al. Evidence for genetic predisposition to desmoid tumours in familial adenomatous polyposis independent of the germline APC mutation. Gut 2004; 53:1832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/38\">",
"      Lefevre JH, Parc Y, Kern&eacute;is S, et al. Risk factors for development of desmoid tumours in familial adenomatous polyposis. Br J Surg 2008; 95:1136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/39\">",
"      Durno C, Monga N, Bapat B, et al. Does early colectomy increase desmoid risk in familial adenomatous polyposis? Clin Gastroenterol Hepatol 2007; 5:1190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/40\">",
"      Clark SK, Phillips RK. Desmoids in familial adenomatous polyposis. Br J Surg 1996; 83:1494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/41\">",
"      Gurbuz AK, Giardiello FM, Petersen GM, et al. Desmoid tumours in familial adenomatous polyposis. Gut 1994; 35:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/42\">",
"      Nieuwenhuis MH, Mathus-Vliegen LM, Slors FJ, et al. Genotype-phenotype correlations as a guide in the management of familial adenomatous polyposis. Clin Gastroenterol Hepatol 2007; 5:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/43\">",
"      Parc YR, Olschwang S, Desaint B, et al. Familial adenomatous polyposis: prevalence of adenomas in the ileal pouch after restorative proctocolectomy. Ann Surg 2001; 233:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/44\">",
"      Friederich P, de Jong AE, Mathus-Vliegen LM, et al. Risk of developing adenomas and carcinomas in the ileal pouch in patients with familial adenomatous polyposis. Clin Gastroenterol Hepatol 2008; 6:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/45\">",
"      Labayle D, Fischer D, Vielh P, et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 1991; 101:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/46\">",
"      Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993; 328:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/47\">",
"      Matsumoto T, Nakamura S, Esaki M, et al. Effect of the non-steroidal anti-inflammatory drug sulindac on colorectal adenomas of uncolectomized familial adenomatous polyposis. J Gastroenterol Hepatol 2006; 21:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/48\">",
"      Giardiello FM, Yang VW, Hylind LM, et al. Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med 2002; 346:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/49\">",
"      Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342:1946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/50\">",
"      Lynch PM, Ayers GD, Hawk E, et al. The safety and efficacy of celecoxib in children with familial adenomatous polyposis. Am J Gastroenterol 2010; 105:1437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/51\">",
"      Cruz-Correa M, Hylind LM, Romans KE, et al. Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study. Gastroenterology 2002; 122:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/52\">",
"      Phillips RK, Wallace MH, Lynch PM, et al. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 2002; 50:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/53\">",
"      Lynch HT, Smyrk T, McGinn T, et al. Attenuated familial adenomatous polyposis (AFAP). A phenotypically and genotypically distinctive variant of FAP. Cancer 1995; 76:2427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/54\">",
"      Galiatsatos P, Foulkes WD. Familial adenomatous polyposis. Am J Gastroenterol 2006; 101:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/55\">",
"      Knudsen AL, Bisgaard ML, B&uuml;low S. Attenuated familial adenomatous polyposis (AFAP). A review of the literature. Fam Cancer 2003; 2:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/56\">",
"      Sieber OM, Segditsas S, Knudsen AL, et al. Disease severity and genetic pathways in attenuated familial adenomatous polyposis vary greatly but depend on the site of the germline mutation. Gut 2006; 55:1440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/57\">",
"      Burt RW, Leppert MF, Slattery ML, et al. Genetic testing and phenotype in a large kindred with attenuated familial adenomatous polyposis. Gastroenterology 2004; 127:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/58\">",
"      Wang L, Baudhuin LM, Boardman LA, et al. MYH mutations in patients with attenuated and classic polyposis and with young-onset colorectal cancer without polyps. Gastroenterology 2004; 127:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/59\">",
"      Balaguer F, Castellv&iacute;-Bel S, Castells A, et al. Identification of MYH mutation carriers in colorectal cancer: a multicenter, case-control, population-based study. Clin Gastroenterol Hepatol 2007; 5:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/60\">",
"      Terdiman JP. MYH-associated disease: attenuated adenomatous polyposis of the colon is only part of the story. Gastroenterology 2009; 137:1883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/61\">",
"      Theodoratou E, Campbell H, Tenesa A, et al. A large-scale meta-analysis to refine colorectal cancer risk estimates associated with MUTYH variants. Br J Cancer 2010; 103:1875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/62\">",
"      Nielsen M, Franken PF, Reinards TH, et al. Multiplicity in polyp count and extracolonic manifestations in 40 Dutch patients with MYH associated polyposis coli (MAP). J Med Genet 2005; 42:e54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/63\">",
"      Kanter-Smoler G, Bj&ouml;rk J, Fritzell K, et al. Novel findings in Swedish patients with MYH-associated polyposis: mutation detection and clinical characterization. Clin Gastroenterol Hepatol 2006; 4:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/64\">",
"      Aretz S, Uhlhaas S, Goergens H, et al. MUTYH-associated polyposis: 70 of 71 patients with biallelic mutations present with an attenuated or atypical phenotype. Int J Cancer 2006; 119:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/65\">",
"      Vogt S, Jones N, Christian D, et al. Expanded extracolonic tumor spectrum in MUTYH-associated polyposis. Gastroenterology 2009; 137:1976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/66\">",
"      Jones N, Vogt S, Nielsen M, et al. Increased colorectal cancer incidence in obligate carriers of heterozygous mutations in MUTYH. Gastroenterology 2009; 137:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/67\">",
"      Win AK, Cleary SP, Dowty JG, et al. Cancer risks for monoallelic MUTYH mutation carriers with a family history of colorectal cancer. Int J Cancer 2011; 129:2256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?16/14/16618/abstract/68\">",
"      Cleary SP, Cotterchio M, Jenkins MA, et al. Germline MutY human homologue mutations and colorectal cancer: a multisite case-control study. Gastroenterology 2009; 136:1251.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2592 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-77.94.48.4-CE85A84A2F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_14_16618=[""].join("\n");
var outline_f16_14_16618=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21761522\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      FAMILIAL ADENOMATOUS POLYPOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Genetic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H520467283\">",
"      Colonic surveillance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H520467604\">",
"      Surveillance for upper intestinal tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H342946992\">",
"      - Spigelman classification of duodenal polyposis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H342946999\">",
"      - Fundic gland polyps",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H342947006\">",
"      - Recommendations from expert groups",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      American Society for Gastrointestinal Endoscopy recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H39185233\">",
"      European guidelines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H55554528\">",
"      Other groups",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Screening for extraintestinal malignancies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21725627\">",
"      Surveillance for benign extraintestinal manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21725661\">",
"      - Adrenal tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21725668\">",
"      - Desmoid tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21725675\">",
"      - Osteomas and dental abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H194153889\">",
"      - Colectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12142671\">",
"      - Chemoprevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Attenuated FAP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      MUTYH ASSOCIATED POLYPOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21761522\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16161335\">",
"      Classic FAP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16161342\">",
"      Attenuated FAP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16161349\">",
"      MUTYH associated polyposis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2592\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2592|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?29/18/29984\" title=\"algorithm 1\">",
"      FAP gene testing algorithm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2592|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/39/31355\" title=\"table 1\">",
"      Modified Spigelmans score and classification",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26950?source=related_link\">",
"      Clinical manifestations and diagnosis of ampullary adenomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/39/17016?source=related_link\">",
"      Clinical manifestations and diagnosis of familial adenomatous polyposis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/33/12826?source=related_link\">",
"      Clinical presentation and evaluation of adrenocortical tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/11/30906?source=related_link\">",
"      Desmoid tumors: Epidemiology, risk factors, molecular pathogenesis, clinical presentation, diagnosis, and local therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/38/11881?source=related_link\">",
"      Desmoid tumors: Systemic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7352?source=related_link\">",
"      Gardner syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/5/29783?source=related_link\">",
"      Lynch syndrome (hereditary nonpolyposis colorectal cancer): Screening and management of patients and families",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/33/30234?source=related_link\">",
"      Molecular genetics of colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/53/29530?source=related_link\">",
"      PTEN hamartoma tumor syndrome, including Cowden syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/23/7541?source=related_link\">",
"      Patient information: Colon and rectal cancer screening (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/34/25123?source=related_link\">",
"      Patient information: Colon and rectal cancer screening (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/30/9698?source=related_link\">",
"      Patient information: Colonoscopy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/11/18611?source=related_link\">",
"      Patient information: Colonoscopy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/47/21234?source=related_link\">",
"      Patient information: Familial adenomatous polyposis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?41/12/42176?source=related_link\">",
"      Patient information: Flexible sigmoidoscopy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/9/3224?source=related_link\">",
"      Peutz-Jeghers syndrome and juvenile polyposis: Screening and management of patients and families",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/56/23431?source=related_link\">",
"      Preimplantation genetic diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/10/37034?source=related_link\">",
"      Screening for colorectal cancer: Strategies in patients at average risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/41/9881?source=related_link\">",
"      Screening for colorectal cancer: Strategies in patients with possible increased risk due to family history",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/8/18569?source=related_link\">",
"      The adrenal incidentaloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13897?source=related_link\">",
"      Treatment of ampullary adenomas",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f16_14_16619="Complicating factors after BMT";
var content_f16_14_16619=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F51151&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F51151&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=12\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Factors predicting complications among febrile stem cell transplant recipients",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Comorbidities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypotension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Altered mental status",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Respiratory failure (PO2 &lt;60 mmHg)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        Uncontrolled bleeding with severe",
"thrombocytopenia (&lt;10,000 platelets/&micro;L)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\">",
"        Serious infections (eg, pneumonia,",
"sepsis, perirectal abscess, typhlitis, meningitis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Symptomatic hypercalcemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inadequate outpatient fluid intake",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Witnessed syncopal episode",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute abdomen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Deep venous thrombosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Uncontrolled hyperglycemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Profound weakness",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_14_16619=[""].join("\n");
var outline_f16_14_16619=null;
var title_f16_14_16620="Antibiotic rx Legionella";
var content_f16_14_16620=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F65315&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F65315&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Antibiotic selection for Legionella infection in adults",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Antimicrobial agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dosing*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Macrolides",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Azithromycin",
"       </td>",
"       <td>",
"        1 g for the first dose, then 500 mg orally or intravenously&bull; every 24 hr",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Clarithromycin",
"       </td>",
"       <td>",
"        500 mg orally or intravenously&Delta; every 12 hr",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Quinolones",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Levofloxacin",
"       </td>",
"       <td>",
"        750 mg orally or intravenously every 24 hr",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Ciprofloxacin",
"       </td>",
"       <td>",
"        400 mg intravenously every 8 hr",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        750 mg orally every 12 hr",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ofloxacin",
"       </td>",
"       <td>",
"        400 mg orally or intravenously every 12 hr",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Moxifloxacin",
"       </td>",
"       <td>",
"        200 mg orally every 24 hr",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Tetracyclines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Doxycycline",
"       </td>",
"       <td>",
"        100 mg orally or intravenously every 12 hr",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Minocycline",
"       </td>",
"       <td>",
"        100 mg orally or intravenously every 12 hr",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tetracycline",
"       </td>",
"       <td>",
"        500 mg orally or intravenously every 6 hr",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tigecycline",
"       </td>",
"       <td>",
"        100 mg intravenously for the first dose, then 50 mg every 12 hours thereafter",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Trimethoprim-sulfamethoxazole",
"       </td>",
"       <td>",
"        160 and 800 mg intravenously every 8 hr",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Doses based on clinical experience and not on controlled trials.",
"     <br>",
"      &bull; Intravenous form not available in some countries.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_14_16620=[""].join("\n");
var outline_f16_14_16620=null;
var title_f16_14_16621="Genetics of mitochondrial myopathies";
var content_f16_14_16621=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F55067&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F55067&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Genetic mutations associated with mitochondrial myopathies",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Mitochondrial DNA mutations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Mutations in genes encoding respiratory chain proteins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Complex I (ND1 and ND4: pure myopathy; ND 5: myopathy with MELAS/LHON/MERRF)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Complex III (Cytochrome b: Exercise intolerance/myalgia - rarely, cardiomyopathy or multisystem disorder)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Complex IV (COX I, COXII, COXIII): Exercise intolerance/myoglobinuria, but also in different patients, severe encephalomyopathy (all three), or MELAS (COX III only)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Mutations impairing protein synthesis in toto",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mutations in transfer RNA most commonly cause MELAS, MERRF; can also cause isolated myopathy, CPEO, or respiratory muscle weakness",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mutations in ribosomal RNA cause aminoglycoside-related deafness and cardiomyopathy but not skeletal myopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Large scale deletions/duplications most often cause of sporadic CPEO/Kearns-Sayre syndrome, less commonly cause Pearson syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Nuclear DNA mutations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Mutations in genes encoding respiratory chain proteins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Coenzyme Q10 deficiency can cause isolated myopathy or rapidly fatal encephalomyopathy of infancy with nephrotic syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Complex I mutations (NDUFS1, 2, 3, 4, 6, 7, 8, NDUFV1, 2, NDUFA1, 2, 11) and complex II mutations (SDHA) can cause autosomal recessive Leigh syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Complex II mutations (SDHB, SDHC, SDHD) can cause paraganglioma and sarcoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Complex III mutations (UQCRB, UQCRQ) can cause lactic acidosis, hypoglycemia and psychomotor retardation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Complex IV mutations (COX6B1, COX4I2) can cause infantile encephalopathy, anemia and pancreatic dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Mutations in ancillary proteins (mutations in nuclear genes encoding proteins needed for the proper assembly or function of the respiratory chain proteins)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Complex I mutations (NDUFAF1, 2, 3, 4, C20orf7, C8orf38, C6orf66) can cause variable disorders including Leigh syndrome and lethal infantile encephalopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Complex II mutations (SDHAF1, 2) can cause infantile leukoencephalopathy and paraganglioma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Complex III mutation (BCS1L) can cause GRACILE syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Complex IV mutations (SURF 1, COX10, COX15, SCO1, SCO2) can cause Leigh syndrome and infantile cardioencephalomyopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Complex V mutations (ATPAF2, TMEM70) can cause encephalopathy and 3-methylglutaconic aciduria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Defects of intergenomic signaling (nuclear gene defects causing multiple deletions or depletion of mitochondrial DNA)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mutations in POLG, C10orf2, RRM2B, SLC25A4, POLG2, and DGUOK can cause autosomal dominant or recessive CPEO",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Mutations in TK2, SUCLA2, SUCLA2, SUCLG1, RRM2B, and DGUOK can cause congenital encephalomyopathy and muscular dystrophy-like encephalomyopathy; TK2 mutations can also cause a slowly progressive generalized myopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Defects of lipid milieu (mutations affecting cardiolipin, an integral part of the inner mitochondrial membrane)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Barth syndrome",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     Barth syndrome: X-linked cardiomyopathy, mitochondrial myopathy and cyclic neutropenia; CPEO: chronic progressive external ophthalmoplegia; GRACILE syndrome: growth retardation, amino aciduria, cholestasis, iron overload, lactic acidosis and early death; Kearns-Sayre syndrome: CPEO with pigmentary retinopathy and onset before age 20; Leigh syndrome: subacute necrotizing encephalomyelopathy; LHON: Leber hereditary optic neuropathy; MELAS: mitochondrial encephalopathy with lactic acidosis and stroke-like episodes; MERRF: myoclonic epilepsy with ragged red fibers; Pearson syndrome: sideroblastic anemia and pancreatic dysfunction.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_14_16621=[""].join("\n");
var outline_f16_14_16621=null;
var title_f16_14_16622="Brain death criteria by country B";
var content_f16_14_16622=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F70736&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F70736&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Criteria for  brain death by country: 2001 International Survey data",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Continent/country",
"      </td>",
"      <td class=\"subtitle1\">",
"       Apnea test",
"      </td>",
"      <td class=\"subtitle1\">",
"       Number of physicians",
"      </td>",
"      <td class=\"subtitle1\">",
"       Observation time, h",
"      </td>",
"      <td class=\"subtitle1\">",
"       Ancillary test",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"5\">",
"       Europe continued",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Slovak Republic",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       Mandatory",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Spain",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       6 (24)&bull;",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Sweden",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       Mandatory",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Switzerland",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       6 (48)&bull;",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Turkey",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       4",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       Mandatory",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Ukraine",
"      </td>",
"      <td>",
"       DVO",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       United Kingdom",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       6",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Yugoslavia",
"      </td>",
"      <td>",
"       DVO",
"      </td>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       Mandatory",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"5\">",
"       Africa",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       South Africa",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Tanzania",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       Mandatory",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Tunisia",
"      </td>",
"      <td>",
"       DVO",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"5\">",
"       Middle East",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Iran",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       12, 24, 36",
"      </td>",
"      <td>",
"       Mandatory",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Israel",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       6 (24)&bull;",
"      </td>",
"      <td>",
"       Mandatory",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Jordan",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       Mandatory",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Lebanon",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       6",
"      </td>",
"      <td>",
"       Mandatory",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Oman",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       6",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Qatar",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       Mandatory",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Saudi Arabia",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       24&bull;",
"      </td>",
"      <td>",
"       Mandatory",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       United Arab Emirates",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"5\">",
"       Asia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Bangladesh",
"      </td>",
"      <td>",
"       DVO",
"      </td>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Georgia",
"      </td>",
"      <td>",
"       DVO",
"      </td>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       24",
"      </td>",
"      <td>",
"       Mandatory",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Hong Kong",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       India",
"      </td>",
"      <td>",
"       DVO",
"      </td>",
"      <td>",
"       4",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       Mandatory",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Indonesia",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       24",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Japan",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       Mandatory",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Korea (South)",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       6",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Malaysia",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       12",
"      </td>",
"      <td>",
"       Mandatory",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Philippines",
"      </td>",
"      <td>",
"       DVO",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       24",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Singapore",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Taiwan",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       1",
"      </td>",
"      <td>",
"       6",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Thailand",
"      </td>",
"      <td>",
"       DVO",
"      </td>",
"      <td>",
"       3",
"      </td>",
"      <td>",
"       6",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\" colspan=\"5\">",
"       Oceania",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Australia, New Zealand",
"      </td>",
"      <td>",
"       PCO",
"       <sub>",
"        2",
"       </sub>",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       2",
"      </td>",
"      <td>",
"       Optional",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PCO2: target PCO",
"     <sub>",
"      2",
"     </sub>",
"     defined (50 or 60 mmHg); A: absent criterion or guideline; DVO: disconnection from ventilatory only; N: neurologist.",
"     <br>",
"      &bull; Observation time can be shortened or eliminated if one confirmatory test is positive for brain death.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Wijdicks, EFM. Brain death worldwide: Accepted fact but no global consensus in diagnostic criteria. Neurology 2002; 58:20. Copyright &copy; 2002 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_14_16622=[""].join("\n");
var outline_f16_14_16622=null;
var title_f16_14_16623="Advantages and disadvantages of initial ART";
var content_f16_14_16623=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F86498&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F86498&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Advantages and disadvantages of antiretroviral components recommended as initial antiretroviral therapy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"2\" width=\"10%\">",
"     </colgroup>",
"     <colgroup span=\"2\" width=\"40%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        ARV class",
"       </td>",
"       <td class=\"subtitle1\">",
"        ARV agent(s)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Advantages",
"       </td>",
"       <td class=\"subtitle1\">",
"        Disadvantages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        NNRTIs (in alphabetical order)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        NNRTI class advantages:",
"        <ul>",
"         <li>",
"          Long half-lives",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        NNRTI class disadvantages:",
"        <ul>",
"         <li>",
"          Greater risk of resistance at the time of treatment failure with NNRTIs than with PIs",
"         </li>",
"         <li>",
"          Potential for cross resistance",
"         </li>",
"         <li>",
"          Skin rash",
"         </li>",
"         <li>",
"          Potential for CYP450 drug interactions",
"         </li>",
"         <li>",
"          Transmitted resistance more common with NNRTIs than with PIs",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        EFV",
"       </td>",
"       <td>",
"        <p>",
"         Virologic responses equivalent or superior to all comparators to date",
"        </p>",
"        <p>",
"         Once-daily dosing",
"        </p>",
"        <p>",
"         Coformulated with TDF/FTC",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Neuropsychiatric side effects",
"        </p>",
"        <p>",
"         Teratogenic in nonhuman primates. Several cases of neural tube defect in infants born to women who were exposed to EFV in the first trimester of pregnancy reported. EFV use should be avoided in women with potential for pregnancy and is contraindicated in the first trimester.",
"        </p>",
"        Dyslipidemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        NVP",
"       </td>",
"       <td>",
"        <p>",
"         No food effect",
"        </p>",
"        <p>",
"         Fewer lipid effects than EFV",
"        </p>",
"        <p>",
"         Once-daily dosing with extended- release tablet formulation",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Higher incidence of rash, including rare but serious HSRs (SJS or TEN), than with other NNRTIs",
"        </p>",
"        <p>",
"         Higher incidence of hepatotoxicity, including serious and even fatal cases of hepatic necrosis, than with other NNRTIs",
"        </p>",
"        <p>",
"         Contraindicated in patients with moderate or severe (Child-Pugh B or C) hepatic impairment",
"        </p>",
"        <p>",
"         Some data suggest that ART-naive patients with high pre-NVP CD4 counts (&gt;250 cells/mm",
"         <sup>",
"          3",
"         </sup>",
"         for females, &gt;400 cells/mm",
"         <sup>",
"          3",
"         </sup>",
"         for males) are at higher risk of symptomatic hepatic events. NVP is not recommended in these patients unless benefit clearly outweighs risk.",
"        </p>",
"        Early virologic failure of NVP + TDF + (FTC or 3TC) in small clinical trials",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        RPV",
"       </td>",
"       <td>",
"        <p>",
"         Once-daily dosing",
"        </p>",
"        <p>",
"         Coformulated with TDF/FTC",
"        </p>",
"        Compared with EFV:",
"        <ul>",
"         <li>",
"          Fewer discontinuations for CNS adverse effects",
"         </li>",
"         <li>",
"          Fewer lipid effects",
"         </li>",
"         <li>",
"          Fewer rashes",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        <p>",
"         More virologic failures in patients with pretreatment HIV RNA &gt;100,000 copies/mL than with EFV-based regimen",
"        </p>",
"        <p>",
"         More NNRTI- and 3TC-associated mutations at virological failure than with regimen containing EFV + two NRTIs",
"        </p>",
"        <p>",
"         Food requirement",
"        </p>",
"        <p>",
"         Absorption depends on lower gastric pH",
"        </p>",
"        <p>",
"         Contraindicated with PPIs",
"        </p>",
"        <p>",
"         RPV-associated depression reported",
"        </p>",
"        Use RPV with caution when coadministered with a drug having a known risk of torsades de pointes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"7\">",
"        PIs (in alphabetical order)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        PI class advantages:",
"        <ul>",
"         <li>",
"          Higher genetic barrier to resistance than NNRTIs and RAL",
"         </li>",
"         <li>",
"          PI resistance uncommon with failure while on first PI regimen",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        PI class disadvantages:",
"        <ul>",
"         <li>",
"          Metabolic complications such as dyslipidemia, insulin resistance, hepatotoxicity",
"         </li>",
"         <li>",
"          GI adverse effects",
"         </li>",
"         <li>",
"          CYP3A4 inhibitors and substrates: potential for drug interactions (more pronounced with RTV-based regimens)",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ATV",
"       </td>",
"       <td>",
"        <p>",
"         Fewer adverse effects on lipids than other PIs",
"        </p>",
"        <p>",
"         Once-daily dosing",
"        </p>",
"        <p>",
"         Low pill burden",
"        </p>",
"        <p>",
"         Good GI tolerability",
"        </p>",
"        Signature mutation (I50L) not associated with broad PI cross resistance",
"       </td>",
"       <td>",
"        <p>",
"         Indirect hyperbilirubinemia sometimes leading to jaundice or scleral icterus",
"        </p>",
"        <p>",
"         PR interval prolongation: generally inconsequential unless ATV combined with another drug with similar effect",
"        </p>",
"        <p>",
"         Cannot be coadministered with TDF, EFV, or NVP (see ATV/r)",
"        </p>",
"        <p>",
"         Nephrolithiasis",
"        </p>",
"        <p>",
"         Skin rash",
"        </p>",
"        <p>",
"         Food requirement",
"        </p>",
"        Absorption depends on food and low gastric pH",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ATV/r",
"       </td>",
"       <td>",
"        <p>",
"         RTV boosting: higher trough ATV concentration and greater antiviral effect",
"        </p>",
"        <p>",
"         Once-daily dosing",
"        </p>",
"        Low pill burden",
"       </td>",
"       <td>",
"        <p>",
"         More adverse effects on lipids than unboosted ATV",
"        </p>",
"        <p>",
"         More hyperbilirubinemia and jaundice than unboosted ATV",
"        </p>",
"        <p>",
"         Food requirement",
"        </p>",
"        <p>",
"         Absorption depends on food and low gastric pH",
"        </p>",
"        <p>",
"         RTV boosting required with TDF and EFV. With EFV, use ATV 400 mg and RTV 100 mg once daily (PI-naive patients only).",
"        </p>",
"        Should not be coadministered with NVP",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        DRV/r",
"       </td>",
"       <td>",
"        <p>",
"         Once-daily dosing",
"        </p>",
"        Potent virologic efficacy",
"       </td>",
"       <td>",
"        <p>",
"         Skin rash",
"        </p>",
"        Food requirement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        FPV/r",
"       </td>",
"       <td>",
"        <p>",
"         Twice-daily dosing resulted in efficacy comparable to LPV/r",
"        </p>",
"        <p>",
"         RTV boosting results in higher trough APV concentration and greater antiviral effect",
"        </p>",
"        <p>",
"         Once-daily dosing possible with RTV 100 mg or 200 mg daily",
"        </p>",
"        No food effect",
"       </td>",
"       <td>",
"        <p>",
"         Skin rash",
"        </p>",
"        <p>",
"         Hyperlipidemia",
"        </p>",
"        <p>",
"         Once-daily dosing results in lower APV concentrations than twice-daily dosing",
"        </p>",
"        <p>",
"         For FPV 1400 mg + RTV 200 mg: requires 200 mg of RTV and no coformulation",
"        </p>",
"        Fewer data on FPV 1400 mg + RTV 100 mg dose than on DRV/r and ATV/r",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        LPV/r",
"       </td>",
"       <td>",
"        <p>",
"         Coformulated",
"        </p>",
"        <p>",
"         No food requirement",
"        </p>",
"        <p>",
"         Recommended PI in pregnant women (twice daily only)",
"        </p>",
"        Greater CD4 count increase than with EFV-based regimens",
"       </td>",
"       <td>",
"        <p>",
"         Requires 200 mg per day of RTV",
"        </p>",
"        <p>",
"         Lower drug exposure in pregnant women. May need dose increase in third trimester.",
"        </p>",
"        <p>",
"         Once-daily dosing not recommended in pregnant women",
"        </p>",
"        <p>",
"         Once-daily dosing results in lower trough concentration than twice-daily dosing",
"        </p>",
"        <p>",
"         Possible higher risk of MI associated with cumulative use of LPV/r",
"        </p>",
"        PR and QT interval prolongation have been reported. Use with caution in patients at risk of cardiac conduction abnormalities or receiving other drugs with similar effect.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SQV/r",
"       </td>",
"       <td>",
"        Similar efficacy but less hyperlipidemia than with LPV/r",
"       </td>",
"       <td>",
"        <p>",
"         Highest pill burden (6 pills per day) among available PI regimens",
"        </p>",
"        <p>",
"         Requires 200 mg of RTV",
"        </p>",
"        <p>",
"         Food requirement",
"        </p>",
"        <p>",
"         PR and/or QT interval prolongations in a healthy volunteer study",
"        </p>",
"        <p>",
"         Pretreatment ECG recommended",
"        </p>",
"        SQV/r is not recommended for patients with any of the following conditions:",
"        <ol>",
"         <li>",
"          Congenital or acquired QT prolongation",
"         </li>",
"         <li>",
"          Pretreatment ECG &gt;450 msec",
"         </li>",
"         <li>",
"          On concomitant therapy with other drugs that prolong QT interval",
"         </li>",
"         <li>",
"          Complete AV block without implanted pacemakers",
"         </li>",
"         <li>",
"          Risk of complete AV block",
"         </li>",
"        </ol>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        INSTI",
"       </td>",
"       <td>",
"        RAL",
"       </td>",
"       <td>",
"        <p>",
"         Virologic response noninferior to EFV",
"        </p>",
"        <p>",
"         Fewer drug-related adverse events and lipid changes than EFV",
"        </p>",
"        <p>",
"         No food effect",
"        </p>",
"        Fewer drug-drug interactions than PI- or NNRTI-based regimens",
"       </td>",
"       <td>",
"        <p>",
"         Twice-daily dosing",
"        </p>",
"        <p>",
"         Lower genetic barrier to resistance than with boosted PI- based regimens",
"        </p>",
"        <p>",
"         No data with NRTIs other than TDF/FTC in ART-naive patients",
"        </p>",
"        <p>",
"         Increase in creatine kinase, myopathy, and rhabdomyolysis have been reported",
"        </p>",
"        Rare cases of severe skin reactions (including SJS and TEN) have been reported and systemic HSRs with rash and constitutional symptoms, with or without hepatitis, have been reported",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CCR5 antagonist",
"       </td>",
"       <td>",
"        MVC",
"       </td>",
"       <td>",
"        <p>",
"         Virologic response noninferior to EFV in post hoc analysis of MERIT study",
"        </p>",
"        Fewer adverse effects than EFV",
"       </td>",
"       <td>",
"        <p>",
"         Requires viral tropism testing prior to initiation of therapy, which results in additional cost and possible delay in initiation of therapy",
"        </p>",
"        <p>",
"         More MVC-treated than EFV-treated patients discontinued therapy due to lack of efficacy in MERIT study",
"        </p>",
"        <p>",
"         Less long-term experience in ART-naive patients than with boosted PI- or NNRTI-based regimens",
"        </p>",
"        <p>",
"         Limited experience with dual-NRTIs other than ZDV/3TC",
"        </p>",
"        <p>",
"         Twice-daily dosing",
"        </p>",
"        CYP 3A4 substrate; dosing depends on presence or absence of concomitant CYP3A4 inducer(s) or inhibitor(s)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        Dual-NRTI pairs (in alphabetical order)",
"       </td>",
"       <td>",
"        ABC/3TC",
"       </td>",
"       <td>",
"        <p>",
"         Virologic response noninferior to ZDV/3TC",
"        </p>",
"        <p>",
"         Better CD4 count responses than with ZDV/3TC",
"        </p>",
"        <p>",
"         Once-daily dosing",
"        </p>",
"        <p>",
"         Coformulation",
"        </p>",
"        <p>",
"         No food effect",
"        </p>",
"        No cumulative TAM-mediated resistance",
"       </td>",
"       <td>",
"        <p>",
"         Potential for ABC HSR in patients with HLA-B*5701",
"        </p>",
"        <p>",
"         Increased potential for cardiovascular events, especially in patients with cardiovascular risk factors",
"        </p>",
"        Inferior virologic responses in patients with baseline HIV RNA &gt;100,000 copies/mL when compared with TDF/FTC in ACTG 5202 study; however, this was not seen in the HEAT study",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        TDF/FTC",
"       </td>",
"       <td>",
"        <p>",
"         Better virologic responses than with ZDV/3TC",
"        </p>",
"        <p>",
"         Better virologic responses than with ABC/3TC in patients with baseline HIV RNA &gt;100,000 copies/mL in ACTG 5202 study; however, this was not seen in the HEAT study",
"        </p>",
"        <p>",
"         Active against HBV; recommended dual- NRTI for HIV/HBV coinfection",
"        </p>",
"        <p>",
"         Once-daily dosing",
"        </p>",
"        <p>",
"         No food effect",
"        </p>",
"        <p>",
"         Coformulated (TDF/FTC, EFV/TDF/FTC, and RPV/TDF/FTC)",
"        </p>",
"        <p>",
"         No cumulative TAM-mediated resistance",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Potential for renal impairment, including Fanconi syndrome and acute renal insufficiency",
"        </p>",
"        <p>",
"         Early virologic failure of NVP + TDF + (FTC or 3TC) in small clinical trials",
"        </p>",
"        Potential for decrease in BMD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ZDV/3TC",
"       </td>",
"       <td>",
"        <p>",
"         Coformulated (ZDV/3TC and ZDV/3TC/ABC)",
"        </p>",
"        <p>",
"         No food effect (although better tolerated with food)",
"        </p>",
"        Preferred dual NRTI in pregnant women",
"       </td>",
"       <td>",
"        <p>",
"         Bone marrow suppression, especially anemia and neutropenia",
"        </p>",
"        <p>",
"         GI intolerance, headache",
"        </p>",
"        <p>",
"         Mitochondrial toxicity, including lipoatrophy, lactic acidosis, hepatic steatosis",
"        </p>",
"        <p>",
"         Compared with TDF/FTC, inferior in combination with EFV",
"        </p>",
"        <p>",
"         Less CD4 increase compared with ABC/3TC",
"        </p>",
"        Twice-daily dosing",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     3TC: lamivudine; ABC: abacavir; APV: amprenavir; ART: antiretroviral therapy; ARV: antiretroviral; ATV: atazanavir; ATV/r: atazanavir/ritonavir; AV: atrioventricular; BMD: bone mineral density; CNS: central nervous system; CYP: cytochrome P; d4T: stavudine; ddI: didanosine; DRV/r: darunavir/ritonavir; ECG: electrocardiogram; EFV: efavirenz; FPV: fosamprenavir; FPV/r: fosamprenavir/ritonavir; FTC: emtricitabine; GI: gastrointestinal; HBV: hepatitis B virus; HSR: hypersensitivity reaction; INSTI: integrase strand transfer inhibitor; LPV/r: lopinavir/ritonavir; MI: myocardial infarction; msec: milliseconds; MVC: maraviroc; NNRTI: non-nucleoside reverse transcriptase inhibitor; NRTI: nucleoside reverse transcriptase inhibitor; NVP: nevirapine; PI: protease inhibitor; PPI: proton pump inhibitor; RAL: raltegravir; RPV: rilpivirine; RTV: ritonavir; SJS: Stevens-Johnson syndrome; SQV/r: saquinavir/ritonavir; TAM: thymidine analogue mutation; TDF: tenofovir; TEN: toxic epidermal necrosis; ZDV: zidovudine.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents.",
"     <a href=\"file://aidsinfo.nih.gov/guidelines\" style=\"FONT-STYLE: italic\" target=\"_blank\">",
"      file://aidsinfo.nih.gov/guidelines",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f16_14_16623=[""].join("\n");
var outline_f16_14_16623=null;
